US20040097436A1 - Triterpenes having antibacterial activity - Google Patents

Triterpenes having antibacterial activity Download PDF

Info

Publication number
US20040097436A1
US20040097436A1 US10/705,022 US70502203A US2004097436A1 US 20040097436 A1 US20040097436 A1 US 20040097436A1 US 70502203 A US70502203 A US 70502203A US 2004097436 A1 US2004097436 A1 US 2004097436A1
Authority
US
United States
Prior art keywords
betulin
alkyl
allobetulin
hydroxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/705,022
Inventor
Pavel Krasutsky
Robert Carlson
Raj Karim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US23651000P priority Critical
Priority to US09/969,556 priority patent/US6689767B2/en
Application filed by University of Minnesota filed Critical University of Minnesota
Priority to US10/705,022 priority patent/US20040097436A1/en
Publication of US20040097436A1 publication Critical patent/US20040097436A1/en
Application status is Abandoned legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/473The waterborne disease being caused by a bacteria the bacteria being Escherichia coli, i.e. E. coli Infection

Abstract

Methods of treating a bacterial infection and of killing or inhibiting bacteria are disclosed. The methods use derivatives of triterpenes that are abundant in birch bark and other plants. The triterpenes include betulin, allobetulin, and lupeol.

Description

    RELATED REFERENCES
  • This application is a divisional of U.S. patent application Ser. No. 09/969,556, filed Oct. 1, 2001, which claims priority from U.S. Provisional Application No. 60/236510, filed on Sep. 29, 2000, which applications are incorporated by reference herein.[0001]
  • BACKGROUND OF THE INVENTION
  • Betulin is a pentacyclic triterpenoid derived from the outer bark of paper birch trees ([0002] Betula paperifera). It can be present at concentrations of up to about 24% of the bark of white birch. Merck Index, twelfth edition, page 1236, 1996. Lupeol is a related compound also found in birch bark and in other plant sources. Lupeol is present at concentrations of about 1.5-3% of birch bark and at up to about 8.2% in Canavalia ensiformis, a plant widespread in the humid tropics of Asia, India, and Africa. Allobetulin is another triterpenoid found in birch bark. A typical pulp mill that processes birch produces enough bark waste to allow for the inexpensive isolation of significant quantities of these triterpenoids.
  • Several triterpenoids have been found to have utility. For example, betulin and related compounds have been shown to have anti-viral activity against herpes simplex virus. Carlson et al., U.S. Pat. No. 5,750,578. [0003]
  • Bacteria are very common pathogens of humans. Among the bacterial species that cause serious disease are the gram negative bacterium [0004] Escherichia coli and gram positive bacteria of the genus Staphylococcus. Staphylococcus aureus is the most serious pathogen of the Staphylococcus bacteria. It is estimated to causes 13% of the 2 million hospital infections each year, and result in 80,000 deaths in the United States. Staphylococcal infections occur most commonly in persons weakened by poor health or immunodeficiency.
  • Antibiotic resistance of bacteria is a growing problem. New agents active against bacteria are needed. A need particularly exists for agents that will act against a range of species, including gram-negative and gram-positive species. Ideally, new agents would also be inexpensive to manufacture. New anti-bacterial agents would be less expensive to manufacture if they were abundant natural products or were easily synthesized from abundant natural products. [0005]
  • SUMMARY OF THE INVENTION
  • The present invention provides a therapeutic method of treating a mammal afflicted with a bacterial infection, the method comprising administering to the mammal an effective antibacterial amount of a triterpene of formula (I): [0006]
    Figure US20040097436A1-20040520-C00001
  • wherein [0007]
  • R[0008] 1 is hydrogen or hydroxy;
  • R[0009] 2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or (C1-C6)alkyl;
  • R[0010] 3 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside;
  • R[0011] 4 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, a glycoside, or amino; or R4 and R5 together are oxo or (═NOH); and
  • R[0012] 5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo or (═NOH);
  • wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C[0013] 6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; —OP(═O)(OH)2; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • each of the bonds represented by—is independently absent or is present; [0014]
  • wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol); [0015]
  • wherein any alkyl is optionally partially unsaturated; [0016]
  • wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C[0017] 1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • or a pharmaceutically acceptable salt thereof. [0018]
  • The present invention also provides a therapeutic method of treating a mammal afflicted with a bacterial infection, the method comprising administering to the mammal an effective anti-bacterial amount of a triterpene of formula (II): [0019]
    Figure US20040097436A1-20040520-C00002
  • wherein [0020]
  • one of R[0021] 1 and R2 is —O—Y and the other is hydrogen or (C1-C6)alkyl optionally substituted by hydroxy, (C1-C6)alkoxy, halo, halo(C1-C6)alkoxy or NRjRk wherein Rj and Rk are independently H, (C1-C6)alkyl or (C1-C6)alkanoyl; or R1 and R2 together are oxo (═O);
  • R[0022] 3 is hydrogen, halo, carboxy, mercapto, (C1-C6)alkyl, (C3-C8)cycloalkyl, or —O—Y;
  • R[0023] 4 and R5 are each independently hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl;
  • R[0024] 6 is hydrogen or is absent when the adjacent—is a bond;
  • R[0025] 7 is hydrogen or (C1-C6)alkyl;
  • R[0026] 8 is hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl and R11 is hydrogen, (C1-C6)alkyl, carboxy, or hydroxy(C1-C6)alkyl; or R8 and R11 together are —O—C(═X)—;
  • R[0027] 9 and R10, are each independently hydrogen or (C1-C6)alkyl;
  • each of the bonds represented by—is independently absent or is present; [0028]
  • X is two hydrogens, oxo (═O) or thioxo (═S); [0029]
  • each Y is independently H, aryl, P(O)(Cl)[0030] 2, (C3-C8)cycloalkyl, adamantyl, —SO2Ra O═P(Rb)2, O═P(Rc)2OP(O)(Rd)—, Si(Re)3, tetrahydropyran-2-yl, an amino acid, a peptide, a glycoside, or a 1 to 10 membered branched or unbranched carbon chain optionally comprising 1, 2, or 3 heteroatoms selected from non-peroxide oxy, thio, and —N(Rf)—; wherein said chain may optionally be substituted on carbon with 1, 2, 3, or 4 oxo (═O), hydroxy, carboxy, halo, mercapto, nitro, —N(Rg)(Rh), (C3-C8)cycloalkyl, (C3-C8)cycloalkyloxy, aryl, aryloxy, adamantyl, adamantyloxy, hydroxyamino, trifluoroacetylamino, a glycoside, an amino acid, or a peptide; and wherein said chain may optionally be saturated or unsaturated (e.g. containing one, two, three or more, double or triple bonds);
  • R[0031] a is (C1-C6)alkyl or aryl;
  • R[0032] b, Rc, and Rd are each independently hydroxy, (C1-C6)alkoxy, hydroxy(C2-C6)alkoxy, adamantyloxy, adamantyl(C1-C6)alkoxy, norbornyloxy, 1,1-di(hydroxymethyl)-2-hydroxyethoxy, carboxy(C1-C6)alkoxy, 2,3-epoxypropyloxy, benzyloxy, (C3-C8)cycloalkyloxy, NRxRy, or aryloxy;
  • R[0033] e is H, aryl or (C1-C6)alkyl;
  • R[0034] f is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl or benzyl;
  • R[0035] g and Rh are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, adamantyl, adamantyl(C1-C6)alkyl, amino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkanoyl, aryl and benzyl; or Rb and Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, or morpholino radical; and
  • R[0036] x and Ry are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, aryl or benzyl;
  • wherein each aryl of Y, R[0037] a—Rd, Rg—Rh, Rx, and Ry may optionally be substituted by 1, 2, or 3 aminosulfonyl, carboxy, NRiRj, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, halo, nitro, cyano, mercapto, carboxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, trifluoromethoxy, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, or (C1-C6)alkanoyloxy; wherein Ri and Rj are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl, or benzyl;
  • wherein any alkyl can optionally be substituted with one or more polyethyleneimine or poly(ethylene glycol); and wherein any alkyl can optionally be interrupted with one or more polyethyleneimine or poly(ethylene glycol); [0038]
  • or a pharmaceutically acceptable salt thereof. [0039]
  • The present invention also provides a method of inhibiting or killing a bacterium, the method comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I): [0040]
    Figure US20040097436A1-20040520-C00003
  • wherein [0041]
  • R[0042] 1 is hydrogen or hydroxy;
  • R[0043] 2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl;
  • R[0044] 3 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside;
  • R[0045] 4 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, a glycoside, or amino; or R4 and R5 together are oxo or (═NOH); and
  • R[0046] 5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo or (═NOH);
  • wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C[0047] 6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; —OP(═O)(OH)2; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • each of the bonds represented by—is independently absent or is present; [0048]
  • wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol); [0049]
  • wherein any alkyl is optionally partially unsaturated; [0050]
  • wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C[0051] 1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • or a pharmaceutically acceptable salt thereof. [0052]
  • The present invention also provides a method of inhibiting or killing a bacterium, the method comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (II): [0053]
    Figure US20040097436A1-20040520-C00004
  • wherein [0054]
  • one of R[0055] 1 and R2 is —O—Y and the other is hydrogen or (C1-C6)alkyl optionally substituted by hydroxy, (C1-C6)alkoxy, halo, halo(C1-C6)alkoxy or NRjRk wherein Rj and Rk are independently H, (C1-C6)alkyl or (C1-C6)alkanoyl; or R1 and R2 together are oxo (═O);
  • R[0056] 3 is hydrogen, halo, carboxy, mercapto, (C1-C6)alkyl, (C3-C8)cycloalkyl, or —O—Y;
  • R[0057] 4 and R5 are each independently hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl;
  • R[0058] 6 is hydrogen or is absent when the adjacent—is a bond;
  • R[0059] 7 is hydrogen or (C1-C6)alkyl;
  • R[0060] 8 is hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl and R11 is hydrogen, (C1-C6)alkyl, carboxy, or hydroxy(C1-C6)alkyl; or R8 and R11 together are —O—C(═X)—;
  • R[0061] 9 and R10, are each independently hydrogen or (C1-C6)alkyl;
  • each of the bonds represented by—is independently absent or is present; [0062]
  • X is two hydrogens, oxo (═O) or thioxo (═S); [0063]
  • each Y is independently H, aryl, P(O)(Cl)[0064] 2, (C3-C8)cycloalkyl, adamantyl, —SO2Ra O═P(Rb)2, O═P(Rc)2OP(O)(Rd)—, Si(Re)3, tetrahydropyran-2-yl, an amino acid, a peptide, a glycoside, or a 1 to 10 membered branched or unbranched carbon chain optionally comprising 1, 2, or 3 heteroatoms selected from non-peroxide oxy, thio, and —N(Rf)—; wherein said chain may optionally be substituted on carbon with 1, 2, 3, or 4 oxo (═O), hydroxy, carboxy, halo, mercapto, nitro, —N(Rg)(Rh), (C3-C8)cycloalkyl, (C3-C8)cycloalkyloxy, aryl, aryloxy, adamantyl, adamantyloxy, hydroxyamino, trifluoroacetylamino, a glycoside, an amino acid, or a peptide; and wherein said chain may optionally be saturated or unsaturated (e.g. containing one, two, three or more, double or triple bonds);
  • R[0065] a is (C1-C6)alkyl or aryl;
  • R[0066] b, Rc, and Rd are each independently hydroxy, (C1-C6)alkoxy, hydroxy(C2-C6)alkoxy, adamantyloxy, adamantyl(C1-C6)alkoxy, norbornyloxy, 1,1-di(hydroxymethyl)-2-hydroxyethoxy, carboxy(C1-C6)alkoxy, 2,3-epoxypropyloxy, benzyloxy, (C3-C8)cycloalkyloxy, NRxRy, or aryloxy;
  • R[0067] e is H, aryl or (C1-C6)alkyl;
  • R[0068] f is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl or benzyl;
  • R[0069] g and Rh are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, adamantyl, adamantyl(C1-C6)alkyl, amino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkanoyl, aryl and benzyl; or Rb and Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, or morpholino radical; and
  • R[0070] x and Ry are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, aryl or benzyl;
  • wherein each aryl of Y, R[0071] a—Rd, Rg—Rh, Rx, and Ry may optionally be substituted by 1, 2, or 3 aminosulfonyl, carboxy, NRiNj, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, halo, nitro, cyano, mercapto, carboxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, trifluoromethoxy, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, or (C1-C6)alkanoyloxy; wherein Ri and Rj are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl, or benzyl;
  • wherein any alkyl can optionally be substituted with one or more polyethyleneimine or poly(ethylene glycol); and wherein any alkyl can optionally be interrupted with one or more polyethyleneimine or poly(ethylene glycol); [0072]
  • or a pharmaceutically acceptable salt thereof. [0073]
  • The present invention provides a therapeutic method of treating a mammal afflicted with a bacterial infection, the method comprising administering to the mammal an effective anti-bacterial amount of a triterpene of formula (I): [0074]
    Figure US20040097436A1-20040520-C00005
  • wherein [0075]
  • R[0076] 1 is hydrogen or hydroxy;
  • R[0077] 2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl;
  • R[0078] 3 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside;
  • R[0079] 4 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside; or R4 and R5 together oxo; and
  • R[0080] 5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo;
  • wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C[0081] 6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; —OP(═O)(OH)2; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • each of the bonds represented by—is independently absent or is present; [0082]
  • wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol); [0083]
  • wherein any alkyl is optionally partially unsaturated; [0084]
  • wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C[0085] 1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • or a pharmaceutically acceptable salt thereof. [0086]
  • The present invention also provides a method of inhibiting or killing a bacterium, the method comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I): [0087]
    Figure US20040097436A1-20040520-C00006
  • wherein [0088]
  • R[0089] 1 is hydrogen or hydroxy;
  • R[0090] 2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl;
  • R[0091] 3 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside;
  • R[0092] 4 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside; or R4 and R5 together are oxo; and
  • R[0093] 5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo;
  • wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C[0094] 6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; —OP(═O)(OH)2; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • each of the bonds represented by—is independently absent or is present; [0095]
  • wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol); [0096]
  • wherein any alkyl is optionally partially unsaturated; [0097]
  • wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C[0098] 1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
  • or a pharmaceutically acceptable salt thereof. [0099]
  • The invention provides novel compounds of formula (I) and formula (II), intermediates for the synthesis of compounds of formula (I) and formula (II), as well as methods of preparing compounds of formula (I) and (II). The invention also provides compounds of formula (I) and (II) that are useful as intermediates for the synthesis of other useful compounds. The invention provides for the use of compounds of formula (I) and formula (II) for the manufacture of medicaments useful for the treatment of bacterial infections in a mammal, such as a human. [0100]
  • DETAILED DESCRIPTION
  • The following definitions are used, unless otherwise described: halo is fluoro, chloro, bromo, or iodo. Alkyl, alkoxy, alkenyl, etc. denote both straight and branched groups; but reference to an individual radical such as “propyl” embraces only the straight chain radical, a branched chain isomer such as “isopropyl” being specifically referred to. Aryl denotes a phenyl radical or an ortho-fused bicyclic carbocyclic radical having about nine to ten ring atoms in which at least one ring is aromatic. [0101]
  • It will be appreciated by those skilled in the art that compounds useful in the invention having a chiral center may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound useful in the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine antibacterial activity using the standard tests described herein, or using other similar tests which are well known in the art. [0102]
  • Specific and preferred values listed below for radicals, substituents, and ranges, are for illustration only; they do not exclude other defined values or other values within defined ranges for the radicals and substituents [0103]
  • Specifically, (C[0104] 1-C6)alkyl can be methyl, ethyl, propyl, isopropyl, butyl, iso-butyl, sec-butyl, pentyl, 3-pentyl, or hexyl; partially unsaturated (C2-C6)alkyl or (C2-C6)alkenyl can be vinyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1,-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, or 5-hexenyl; (C1-C5)alkanoyl can be carbonyl, acetyl, propanoyl, butanoyl, isopropanoyl, or pentenoyl; (C1-C6)alkoxy can be methoxy, ethoxy, propoxy, isopropoxy, butoxy, iso-butoxy, sec-butoxy, pentoxy, 2-pentoxy, 3-pentoxy, or hexyloxy; halo(C1-C6)alkoxy can be trifluoromethyloxy, 2-chloroethyloxy, 3,3-dichloropropyloxy, or 4,4,4-trifluorobutyloxy; (C3-C8)cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; (C3-C8)cycloalkyloxy can be cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, or cyclooctyloxy; hydroxy(C1-C6)alkoxy can be hydroxymethoxy, 1-hydroxyethoxy, 2-hydroxyethoxy, 1-hydroxypropoxy, 2-hydroxypropoxy, 3-hydroxypropoxy, 1-hydroxybutoxy, 4-hydroxybutoxy, 1-hydroxypentoxy, 5-hydroxypentoxy, 1-hydroxyhexoxy, or 6-hydroxyhexoxy; amino(C1-C6)alkyl can be aminomethyl, 1-aminoethyl, 2-aminoethyl, 1-aminopropyl, 2-aminopropyl, 3-aminopropyl, 1-aminobutyl, 2-aminobutyl, 3-aminobutyl, 4-aminobutyl, 1-aminopentyl, 2-aminopentyl, 3-aminopentyl, 5-aminopentyl, 1-aminohexyl, 2-aminohexyl, 3-aminohexyl, or 6-aminohexyl; (C1-C6)alkoxycarbonyl can be methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl, 2-methylpropyloxycarbonyl, butyloxycarbonyl, pentyloxycarbonyl, or hexyloxycarbonyl; (C1-C6)alkanoyloxy can be carbonyloxy, acetyloxy, propanoyloxy, butanoyloxy, 2-methylpropanoyloxy, 2-methylbutanoyloxy, 3-methylbutanoyloxy, pentanoyloxy, or hexanoyloxy.
  • “3-carboxypropenoyloxymethyl” refers to the group —CH[0105] 2OC(═O)CH═CHCOOH;
  • “aminoacetoxymethyl” refers to the group —CH[0106] 2OC(═O)CH2NH2;
  • “(carboxymethoxy)acetoxymethyl” refers to the group —CH[0107] 2OC(═O)CH2OCH2COOH;
  • “4-carboxybutanoyloxymethyl” refers to the group —CH[0108] 2OC(═O)CH2CH2CH2COOH;
  • “2-carboxybenzoyloxymethyl” refers to the group [0109]
    Figure US20040097436A1-20040520-C00007
  • “butanoyloxymethyl” refers to the group —CH[0110] 2OC(═O)CH2CH2CH3;
  • “2-carboxybenzoyl” refers to the group [0111]
    Figure US20040097436A1-20040520-C00008
  • “2-amino-3-methylbutanoyl” refers to the group —C(═O)CH[0112] 2(NH2)CH2(CH3)2;
  • “3-carboxypropenoyl” refers to the group —C(═O)CH═CHCOOH; [0113]
  • “aminoacetyl” refers to the group —C(═O)CH[0114] 2NH2;
  • “4-carboxybutanoyl” refers to the group —C(═O)CH[0115] 2CH2CH3COOH,
  • “(carboxymethoxy)acetyl” refers to the group —C(═O)CH[0116] 2OCH2COOH,
  • “3-(3,4-dihydroxyphenyl)propenoyl” refers to the group [0117]
    Figure US20040097436A1-20040520-C00009
  • “carboxymethylenethioacetyl” refers to the group —C(═O)CH[0118] 2SCH2COOH;
  • “3-carboxy-3-methylbutanoyl” refers to the group —C(═O)CH[0119] 2C(COOH)(CH3)2;
  • “oxime” refers to the group (═NOH) that is substituted directly on a carbon atom, thereby providing the group C═N—OH. [0120]
  • The term “amino acid,” comprises the residues of the natural amino acids (e.g. Ala, Arg, Asn, Asp, Cys, Glu, Gln, Gly, His, Hyl, Hyp, Ile, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val) in D or L form, as well as unnatural amino acids (e.g. phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, gamma-carboxyglutamate; hippuric acid, octahydroindole-2-carboxylic acid, statine, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine, ornithine, citruline, α-methyl-alanine, para-benzoylphenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine). The term also comprises natural and unnatural amino acids bearing a conventional amino protecting group (e.g. acetyl or benzyloxycarbonyl), as well as natural and unnatural amino acids protected at the carboxy terminus (e.g. as a (C[0121] 1-C6)alkyl, phenyl or benzyl ester or amide; or as an α-methylbenzyl amide). Other suitable amino and carboxy protecting groups are known to those skilled in the art (See for example, T. W. Greene, Protecting Groups In Organic Synthesis; Wiley: New York, Third Edition, 1999, and references cited therein). An amino acid can be linked to the remainder of a compound of formula I or II through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of cysteine.
  • The term “peptide” describes a sequence of 2 to 25 amino acids (e.g. as defined herein) or peptidyl residues. The sequence may be linear or cyclic. For example, a cyclic peptide can be prepared or may result from the formation of disulfide bridges between two cysteine residues in a sequence. A peptide can be linked to the remainder of a compound of formula I or II through the carboxy terminus, the amino terminus, or through any other convenient point of attachment, such as, for example, through the sulfur of a cysteine. Preferably a peptide comprises 3 to 25, or 5 to 21 amino acids. Peptide derivatives can be prepared as disclosed in U.S. Pat. Nos. 4,612,302; 4,853,371; and 4,684,620. [0122]
  • Glycosides are formed by reacting mono-, di- and polysaccharides with 1-2 hydroxyl groups of the compound of formula (I) or formula (II), including glucose, glucuronic acid, mannose, galactose, sorbase, ribose, maltose, sucrose, modified cellulosics, dextrans, modified starches and the like. These derivatives can advantageously exhibit improved water solubility over betulin itself. See, [0123] Remington's Pharmaceutical Sciences, A. R. Gennaro, ed., Mack Pub. Co. (18th ed., 1990) at pages 384-386. Glycoside derivatives can be prepared as described in PCT Applications WO 96/34005 and 97/03995.
  • “Polyethyleneimine” refers to the group (—NHCH[0124] 2CH2—)x[—N(CH2CH2NH2)CH2CH2—]y. Polyethyleneimine can be attached to a compound of formula I or II through either of the nitrogen atoms marked with hash marks. “Poly(ethylene glycol)” refers to the compound H(OCH2CH2)nOH. It can be attached to a compound of formula I or II through the terminal hydroxyl group.
  • The term “partially unsaturated” refers to a linear or branched hydrocarbon having one or more carbon-carbon double bonds. [0125]
  • The term “phosphono” refers to O═P(OH)[0126] 2—.
  • The term “direct bond” refers to a group being absent. [0127]
  • Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” is meant herein a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious antibacterial agent. [0128]
  • The term “bacterium” or “bacteria” refers to any prokaryotic organism. [0129]
  • The structure and carbon numbering of three exemplary compounds of the present invention are shown below. [0130]
    Figure US20040097436A1-20040520-C00010
  • Specific values for compounds of formula (I) are as follows: A specific value for the bond between carbons 1 and 2 is a single bond. [0131]
  • Another specific value for the bond between carbons 1 and 2 is a double bond. [0132]
  • A specific value for R[0133] 1 is hydrogen.
  • Another specific value for R[0134] 1 is hydroxy.
  • A specific value for R[0135] 2 is a direct bond.
  • A specific value for R[0136] 3 is(C1-C6)alkyl; wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino, (C6-C10)aryl, or —OP(═O)(OH)2; any alkyl is optionally interrupted on carbon with one or more oxy or thio; any alkyl is optionally partially unsaturated; and any aryl can optionally be substituted with one or more hydroxy or carboxy.
  • Another specific value for R[0137] 3 is 3-carboxypropenoyloxymethyl, aminoacetoxymethyl, (carboxymethoxy)acetoxymethyl, 4-carboxybutanoyloxymethyl, 2-carboxybenzoyloxymethyl, butanoyloxymethyl, or —CH2OC(═O)OP(═O)(OH)2.
  • A specific value for R[0138] 4 is (C1-C6)alkyl; wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino, (C6-C10)aryl, or —OP(═O)(OH)2; any alkyl is optionally interrupted on carbon with one or more oxy or thio; any alkyl is optionally partially unsaturated; and any aryl can optionally be substituted with one or more hydroxy or carboxy.
  • Another specific value for R[0139] 4is 2-carboxybenzoyl, 2-amino-3-methylbutanoyl, 3-carboxypropenoyl, aminoacetyl, 4-carboxybutanoyl, (carboxymethoxy)acetyl, 3-(3,4-dihydroxyphenyl)propenoyl, carboxymethylenethioacetyl, 3-carboxy-3-methylbutanoyl, amino, —P(═O)(OH)2, oxo, or (═NOH).
  • A specific value for R[0140] 5 is oxy or a direct bond.
  • A specific group of compounds are compounds of formula (I) wherein R[0141] 1 is hydrogen or hydroxy; R2 is a direct bond; R3 is (C1-C5)alkoxymethyl or hydroxymethyl; R4 is hydrogen, phosphono, sulfo, or (C1-C6)alkyl, and R5 is oxy; or R4 is amino and R5 is a direct bond; or R4and R5 together are oxo or (═NOH); wherein any alkyl, or alkyl segment of an R group, is optionally interrupted on carbon with one or more oxy, thio, or imido; wherein any alkyl, or alkyl segment of an R group, can optionally be substituted with one or more oxo, carboxy, amino, —OP(═O)(OH)2, or phenyl; wherein phenyl can optionally be substituted with one or more hydroxy or carboxy.
  • Another specific group of compounds are compounds of formula (I) wherein R[0142] 1 is hydrogen or hydroxy; R2 is a direct bond; R3 is 3-carboxypropenoyloxymethyl, aminoacetoxymethyl, (carboxmethoxy)acetoxymethyl, 4-carboxybutanoyloxymethyl, 2-carboxybenzoyloxymethyl, butanoyloxymethyl, or —CH2OC(═O)OP(═O)(OH)2; R4 is 2-carboxybenzoyl, 2-amino-3-methylbutanoyl, 3-carboxypropenoyl, aminoacetyl, 4-carboxybutanoyl, (carboxymethoxy)acetyl, 3-(3,4-dihydroxyphenyl)propenoyl, carboxymethylenethioacetyl, 3-carboxy-3-methylbutanoyl, amino, —P(═O)(OH)2, oxo, or (═NOH); and R5 is oxy or a direct bond.
  • Another specific group of compounds of formula (I) is betulin; betulin-3,28-diglycine; betulin-28-glycerol oxalate; betulin-28-glycine; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28didiglycolate; betulin-3,28-diglycine; betulin-3-maleate; betulin-3,28-di-(L-Glutamic acid r-benzylester) ester; betulin-3,28-di-L-alanine; betulin-3,28-di-L-proline; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-diphenylalanine; betulin-3-28-dioxalate-polyethylene amine; betulin-3,38-diphosphate; betulin-3-caffeate; betulin-3,28-(3′,3′-dimethyl) glutarate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-di(3′,3′-dimethyl)glutarate; betulin-3,28-didiglycolate; betulin-3,28-di(thiodiglycolate); betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-phenylalanine; betulin-3,28—di-L-valine; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=1448); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 crude); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; betulin-3,28-(dipoly(ethylene glycol)bis (carboxymethylester); allobetulin-3,28-(dipoly(ethylene glycol)bis (carboxymethyl ester); hederin hydrate; lupeol; lupeol-3-glutarate; lupeol-3-succinate; lupeol-3-thiodiglycolate; lupeol-3-phthalate; lupeol-3-succinate; oleanolic acid; ursolic acid; or uvaol. [0143]
  • Another specific group of compounds of formula (I) is betulin; betulin-28-glycerol oxalate; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28-didiglycolate; betulin-3,28-diglycine; betulin-3,28-di-(L-glutamic acid γ-benzylester) ester; betulin3,28-di-L-proline ester; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-dioxalate-polyethylene amine; betulin-3,28-diphosphate; betulin-3-caffeate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-dithiodiglycolate; betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-phenylalanine; betulin-di-L-valine; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; betulin-3,28-(dipoly(ethylene glycol)bis (carboxymethylester); hederin hydrate; lupeol-3-glutarate; lupeol-3-succinate; lupeol-3-thiodiglycolate; lupeol-3-phthalate; oleanolic acid; or uvaol. [0144]
  • Another specific group of compounds of formula (I) is betulin-3-caffeate; betulin-28-diglycolate; betulin-3,28-diglutarate; betulin-3,28-diglycine; betulin-3,28-didiglycolate; betulin-3,28-dimaleate; betulin-3,28-diphosphate; betulin-3,28-diphthalate; betulin-3,28-di-L-valine; lupeol; lupeol-3-amine; lupeol-3-(3′,3′-dimethyl)succinate; lupeol-3-maleate; lupeol-3-phosphate; lupeol-3-thiodiglycolate; lupenone; lupenon-1,2-ene-2-ol; or lupenon-3-oxime. [0145]
  • A specific group of compounds of formula (II) is 3-β-acetoxy-19αH-19,28 lactone oleanan; allobetulin; allobetulin-3-succinate; allobetulin-3-glycine ester; allobetulin lactone; allobetulin lactone-3-acetate; allobetulin lactone-3-phosphate; allobetulin-3-L-alanine; allobetulin-3-L-valine; allobetulin-3-L-proline; allobetulin-3-succinate; allobetulin-3-diglycolate; allobetulin-3-glutarate; allobetulin-3-phthalate; allobetulin-3-methylenamine; allobetulin-3-ethanolamine; allobetulin-3-ethanolamine hydrochloride; allobetulin-3-glycolate; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulin-3-(polyethylene glycol)-COOH (Mw=674); allobetulon; allobetulon lactone-1-ene-2ol; allobetulon lactone-1-en-2-succinate; allobetulon-1-ene-2-ol; allobetulon-1-ene-2-diglycolate; 3-allobetulon-1-ene-2-succinate; or 3-allobetulon-1-ene-2-diglycolate. [0146]
  • Another specific group of compounds of formula (II) are 3-β-acetoxy-19αH-19,28 lactone oleanan; allobetulin; allobetulin-3-glycine ester; allobetulin lactone-3-phosphate; allobetulin-3-succinate; allobetulin-3-ethanolamine; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulon; allobetulon lactone-l-ene-2-ol; 3-allobetulon-1-ene-2-succinate; or ursolic acid. [0147]
  • A specific method of the invention is the method of treating a mammal afflicted with a bacterial infection comprising administering to the mammal an effective anti-bacterial amount of a compound of formula (I) or formula (II), wherein the bacterial infection is caused by [0148] Escherichia coli, Staphylococcus sp., Enterococcus faecalis, or a combination thereof.
  • Another specific method of the invention is the method of treating a mammal afflicted with a bacterial infection comprising administering to the mammal an effective anti-bacterial amount of a compound of formula (I) or formula (II), wherein the bacterial infection is caused by [0149] Staphylococcus aureus.
  • Another specific method of the invention is the method of inhibiting or killing a bacterium or bacteria comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I) or formula (II), wherein the bacterium is [0150] Escherichia coli, Staphylococcus sp., Enterococcus faecalis, or a combination thereof.
  • Another specific method of the invention is the method of inhibiting or killing a bacterium or bacteria comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I) or formula (II) wherein the bacterium is [0151] Staphylococcus aureus.
  • Another specific method of the invention is the method of inhibiting or killing a bacterium or bacteria comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I) wherein the contacting is in vivo. [0152]
  • Another specific method of the invention is the method of inhibiting or killing a bacterium or bacteria comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I) wherein the contacting is in vitro. [0153]
  • Another specific method of the invention is the method of inhibiting or killing a bacterium or bacteria comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (II) wherein the contacting is in vivo. [0154]
  • Another specific method of the invention is the method of inhibiting or killing a bacterium or bacteria comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (II) wherein the contacting is in vitro. [0155]
  • Specific triterpenes of formula (I) having antibacterial activity are shown below in Table 1 below. [0156]
    TABLE 1
    Specific compounds of formula (I) having anti-bacterial activity.
    Name R1 R2 R3 R5 R4 Active against
    Betulin-3- caffeate H
    Figure US20040097436A1-20040520-C00011
    —O—
    Figure US20040097436A1-20040520-C00012
    E. coli
    Betulin-28- H —CH2OC(═O)CH2OCH2COOH —O— H E. coli
    diglycolate
    Betulin-3,28- H —CH2OC(═O)CH2CH2CH2COOH —O— —C(═O)CH2CH2CH2COOH E. coli
    diglutarate
    Betulin-3,28- H —CH2OC(═O)CH2NH2 —O— —C(═O)CH2NH2 E. coli
    diglycine
    Betulin-3,28- H —CH2OC(═O)CH2OCH2COOH —O— —C(═O)CH2OCH2COOH E. coli
    didiglycolate
    Betulin-3,28- H —CH2OC(═O)CH═CHCOOH —O— —C(═O)CH═CHCOOH S. aureus,
    dimaleate S. aureus methicillin
    resistant
    Betulin-3,28- H —CH2O—P(═O)(OH)2 —O— —P(═O)(OH)2 E. coli
    diphosphate
    Betulin-3,28- diphthalate H
    Figure US20040097436A1-20040520-C00013
    —O—
    Figure US20040097436A1-20040520-C00014
    S. aureus
    Betulin-3,28-di- H —CH2OC(═O)— —O— —C(═O)— S. aureus
    L-valine CH2(NH2)CH(CH3)2 CH2(NH2)CH(CH3)2
    Lupeol H —CH3 —O— H S. aureus,
    S. epidermidis
    Enterococcus
    faecalis
    Lupeol-3-amine H —CH3 H S. aureus,
    E. faecalis
    Lupeol-3-(3′,3′, H —CH3 —O— —CH2OC(═O)CH2C(CH3)2COOH S. aureus
    dimethyl)
    succinate
    Lupeol-3- H —CH3 —O— —P(═O)(OH)2 S. aureus,
    phosphate E. faecalis
    Lupeol-3- H —CH3 —O— —C(═O)CH2SCH2COOH S. aureus,
    thiodiglycolate S. epidermidis,
    E. faecalis
    Lupeol-3- H —CH3 —O— —C(═O)CH═CHCOOH S. aureus,
    maleate S. epidermidis,
    E. faecalis
    Lupenone H —CH3 (═O) S. aureus,
    E. faecalis
    Lupenon-3- H —CH3 (═NOH) S. aureus,
    oxime E. faecalis
    Lupenon-1,2- H —CH3 (═O) S. aureus,
    ene-2-ol S. epidermidis,
    E. faecalis
  • Processes for preparing compounds of formula (I) and formula (II) are provided as further embodiments of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified. Specifically, the compounds of formula (I) or formula (II) can be prepared from convenient starting materials, employing procedures (e.g., reagents and reaction conditions) known to those of skill in the art. For example, suitable reagents and reaction conditions are disclosed, e.g., in [0157] Advanced Organic Chemistry, Part B: Reactions and Synthesis, Second Edition, Carey and Sundberg (1983); Advanced Organic Chemistry, Reactions, Mechanisms, and Structure, Second Edition, March (1977); Greene, T. W.; Wutz, P. G. M. Protecting Groups In Organic Synthesis, Second Edition, 1991, New York, John Wiley & sons, Inc.; and Comprehensive Organic Transformations, Second Edition, Larock (1999). Additionally, specific exemplary procedures are shown in the examples herein below.
  • In cases where compounds are sufficiently basic or acidic to form stable nontoxic acid or base salts, administration of the compounds as salts may be appropriate. Examples of pharmaceutically acceptable salts are organic acid addition salts formed with acids which form a physiological acceptable anion, for example, tosylate, methanesulfonate, acetate, citrate, malonate, tartarate, succinate, benzoate, ascorbate, α-ketoglutarate, and α-glycerophosphate. Suitable inorganic salts may also be formed, including hydrochloride, sulfate, nitrate, bicarbonate, and carbonate salts. [0158]
  • Pharmaceutically acceptable salts may be obtained using standard procedures well known in the art, for example by reacting a sufficiently basic compound such as an amine with a suitable acid affording a physiologically acceptable anion. Alkali metal (for example, sodium, potassium or lithium) or alkaline earth metal (for example calcium) salts of carboxylic acids can also be made. [0159]
  • The compounds of formula I or II can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes. [0160]
  • Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incorporated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1% of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained. [0161]
  • The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incorporated into sustained-release preparations and devices. [0162]
  • The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. [0163]
  • The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form should be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin. [0164]
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions. [0165]
  • For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid. [0166]
  • Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers. [0167]
  • Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user. [0168]
  • Examples of useful dermatological compositions which can be used to deliver the compounds of formula I or II to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508). [0169]
  • Useful dosages of the compounds of formula I or II can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949. [0170]
  • Generally, the concentration of the compound(s) of formula I or II in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%. [0171]
  • The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician. [0172]
  • In general, however, a suitable dose will be in the range of from about 0.5 to about 100 mg/kg, e.g., from about 10 to about 75 mg/kg of body weight per day, such as 3 to about 50 mg per kilogram body weight of the recipient per day, preferably in the range of 6 to 90 mg/kg/day, most preferably in the range of 15 to 60 mg/kg/day. [0173]
  • The compound is conveniently administered in unit dosage form; for example, containing 5 to 1000 mg, conveniently 10 to 750 mg, most conveniently, 50 to 500 mg of active ingredient per unit dosage form. [0174]
  • Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 to about 75 μM, preferably, about 1 to 50 μM, most preferably, about 2 to about 30 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 1-100 mg of the active ingredient. Desirable blood levels may be maintained by continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s). [0175]
  • The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye. [0176]
  • The ability of a compound of the invention to act as an antibacterial agent may be determined using pharmacological models which are well known to the art, including the tests described in the Examples below. [0177]
  • The compounds of the invention may be also be useful as pharmacological tools for the further investigation of the mechanism of their antibacterial action. [0178]
  • The compounds of the invention can also be administered in combination with other therapeutic agents that are effective to treat bacterial infections, or to inhibit or kill a bacteria. [0179]
  • The system used to name the compounds of the invention will be clear to one of skill in the art based on the following examples. Names generally consist of the base structure, e.g., betulin, allobetulin, or lupeol, followed by a substituent. For example, betulin-28-succinate, with the structure shown in Example 1, consists of a succinic acid molecule esterified to the hydroxyl at carbon 28 of betulin. If no number is given for the substituent, the substitent is attached to the hydroxyl at carbon 3 on the base structure. [0180]
  • Betulin-3-glycerol oxalate is a compound of formula (I), wherein R[0181] 4 and R5 together are hydroxyl, R2 and R3 together are —OC(═O)C(═O)OCH2CH(OH)CH2OH, and R1 is hydrogen. Betulin-1-ene-2-ol is a compound of formula (I), wherein the bond between carbons 1 and 2 is a double bond, R1 is hydroxyl, R2 and R3 together are hydroxymethyl, and R4 and R5 together are oxo. Uvaol is a compound of formula (II), wherein R10 is methyl, R9 is hydrogen, R8 is methyl, R7 is hydrogen, R11 is hydroxymethyl, R6 is absent and the bond between carbons 12 and 13 is double, R3 is hydrogen, R4 and R5 are methyl, R2 is hydrogen, and R1 is hydroxy. Oleanolic acid has the same structure as uvaol, except it has a carboxy at R11 instead of hydroxymethyl. The structure of hederin hydrate is disclosed at page 871 of the Aldrich Chemical Co. 2000-2001 catalog. The structure of other named compounds can be found in standard sources such as the Merck Index. “Betulin arabinose galactan” refers to betulin in a solution of arabino-galactan.
  • Unless otherwise stated, amino acid substituents are attached to the compounds of the invention through their carboxyl groups via ester linkages. Thus, betulin-3,28-diglycine is the same compound as betulin-3,28-diglycine ester. [0182]
  • The invention will now be illustrated by the following non-limiting Examples.[0183]
  • EXAMPLES Example 1 Betulin-28-succinate
  • [0184]
    Figure US20040097436A1-20040520-C00015
  • Betulin-28-succinate [0185]
  • m=0.200 g [0186]
  • C[0187] 34H54O5
  • Exact Mass: 542.40 [0188]
  • Mol. Wt.: 542.79 [0189]
  • C, 75.23; H, 10.03; O, 14.74 [0190]
  • Place Betulin 1.00 g (1 equivalent) along with Succinic anhydride 0.249 g (1.1 equivalent) and imidazole 0.462 g (3 equivalent) in a 25 ml flask. Add 20 ml dried dichloromethane, stir and reflux for 24 hours. After the reaction completes, add 10 ml 3% HCl, shake gently. The pH should be 2. Separate the organic part. Use dichloromethane (3×5 ml) to extract the water layer. Combine the organic part and use 3% HCI (2×10 ml) to wash it. Use Na[0191] 2SO4 (anhy.) to dry the organic part. Evaporate the solvent, get white powder 1.10 g. Use small amount of acetone to tritrate the white product. After drying, get 0.90 g white granular solid with yield 73.2%. M.P.: 234.1-235.5° C.; 1R (KBr): 3355.76, 2953.19, 1734.29, 1708.63, 1264.63, 1174.11 cm−1; 1H NMR (CDCl3): δ4.69 (S, 1H), 4.59 (S, 1H), 4.32 (D, J=11.1 Hz, 1H), 3.91 (D, J=11.1 Hz), 3.22 (M, 1H), 2.68 (M, 4H), 2.44 (M, 1H), 1.68 (S, 3H), 0.76, 0.82, 0.97, 1.02 (All S, 4×3H), 0.71-2.1 (complex, 28H); 13C NMR (CDCl3): 172.43, 167.96, 145.61, 105.38, 74.56, 58.71, 50.80, 45.88, 44.32, 43.21, 41.94, 38.21, 36.38, 34.36, 34.21, 33.12, 32.66, 30.01, 29.68, 25.23, 25.08, 24.57, 24.37, 23.50, 22.87, 22.54, 20.71, 16.30, 14.67, 13.79, 11.62, 11.54, 10.89, 10.30;
  • Example 2 Betulin-3,28-disuccinate
  • [0192]
    Figure US20040097436A1-20040520-C00016
  • Betulin-3,28-disuccinate [0193]
  • m=0.200 g [0194]
  • C[0195] 38H58O8
  • Exact Mass: 642.41 [0196]
  • Mol Wt.: 642.86 [0197]
  • C, 71.00; H, 9.09; O, 19.91 [0198]
  • Place 0.5 g Betulin along with 0.34 g succinic anhydride and 0.46 g imidazole in a 25 ml flask. Add 15 ml CH[0199] 2Cl2 (dried) and reflux for 12 hours. Add 10 ml 3% HCl, separate the organic part, use CH2Cl2 (3×5 ml) to wash, and combine the organic parts. Use 3% HCl (2×10 ml) wash the organic part, then use Na2SO4 to dry it. Evaporating the solvent gives 0.73 g yellow powder. Useing CHCl3-hexane to crystalize gives 0.65 g yellow powder. Or stiring the solid with 3% HCl in the warm condition for 12 hours, followed by filtration and drying, gives 0.60 g powder with yield 82.5%. M.P. (decomp.) 116.1-117.8° C.; IR(KBr): 2954.83, 1726.44, 1169.46 cm−1; 1H NMR (CDCl3): 4.69 (S, 1H), 4.59 (S, 1H), 4.51 (M, 1H), 4.31 (D, J=11.4 Hz, 1H), 3.88 (D, J=10.8 Hz, 1H), 2.67 (M, 8H), 2.44 (M, 1H), 1.68 (S, 3H), 1.3, 0.98, 0.85, 0.86, 0.79 (all S, 5×3H), 1.06-2.1 (complex, 24H); 13C NMR (CDCl3): 173.73, 173.65, 167.98, 167.37, 145.63, 105.44, 77.09, 58.72, 50.91, 45.77, 44.30, 43.25, 41.94, 38.22, 36.40, 33.88, 33.36, 33.10, 32.56, 29.97, 29.61, 25.18, 24.87, 24.61, 23.41, 22.54, 20.67, 19.13, 16.34, 14.65, 13.69, 12.04, 11.68, 11.55, 1031;
  • Example 3 Betulin-28-phthalate
  • [0200]
    Figure US20040097436A1-20040520-C00017
  • Betulin-28-phthalate [0201]
  • C[0202] 38H54O5
  • Exact Mass: 590.40 [0203]
  • Mol. Wt.: 590.83 [0204]
  • C, 77.25; H, 9.21; O, 13.54 [0205]
  • Place Betulin 1 g (1 equivalent) and imidazole 0.31 g (4 equivalents) with phthalic anhydride 0.35 g (1.05 equivalents) in a 15 mL flask. Add 5 mL of 1-methyl-2-pyrrolidinone and stir at room temperature for 48 hours. Pour the mixture into the water with strong stirring and adjust pH around 3. Stir for 2-3 hours. All the chunks should become small particles. After filtration, use water to wash three times, and then dry it in the oven. Get 1.25 g white solid. Use ethyl acetate: Hexane (1:4) to elute the product from the silica gel column and get 0.69 g white prism solid. Yield is 51.5%. M.P.: 205.2-206.9° C. JR(cm[0206] −1): 3500.0, 2957.0, 2876.4, 1719.7, 1458.2, 1386.5, 1289.8, 1136.8, 1072.4; 1H NMR (CDCl3, ppm): 7.93 (D, 1H, J=6.9 Hz), 7.73 (D, 1H, J=6.6 Hz), 7.59 (M, 2H), 4.71 (S, 1H), 4.60 (S, 1H), 4.53 (D, 1H, J=8.4 Hz), 4.14 (D, 1H, J=10.8 Hz), 3.22 (M, 1H), 2.51 (M, 1H), 1.69 (S, 3H), 1.05, 0.97, 0.95, 0.82, 0.76 (all S, 5×3H), 2.2-0.6 (Complex, 26H); 13C NMR (CDCl3, ppm): 171.85, 169.03, 150.46, 133.90, 132.46, 131.13, 130.35, 129.19, 110.25, 79.43, 66.23, 64.90, 55.60, 50.69, 49.26, 48.08, 46.83, 43.07, 41.12, 39.18, 39.04, 38.01, 37.48, 34.92, 34.41, 30.11, 29.92, 28.34, 27.69, 27.37, 25.54, 21.14, 19.53, 18.58, 16.45, 16.38, 15.75, 15.61, 15.14.
  • Example 4 Lupeol-3-phthalate
  • [0207]
    Figure US20040097436A1-20040520-C00018
  • Lupeol-3-phthalate [0208]
  • C[0209] 38H54O4
  • Exact Mass: 574.40 [0210]
  • Mol. Wt.: 574.83 [0211]
  • C, 79.40; H, 9.47; 0, 11.13 [0212]
  • Place Lupeol 0.100 g and imidazole 0.96 g with 0.069 g phthalic anhydride in a 25 mL flask, add dried dichloromethane 10 mL and reflux for 24 hours. Then use 3% HCl (3×5 mL) to wash the organic part, which is followed by drying with, sodium sulfate (anhy.). After evaporate the solvent, receive white powder, which is followed by stirring with 3% HCl for 12 hours. Then filter and dry the white solid in the oven. This results in 0.128 g white product with 94.8% yield. M.P.: 160.2-162.1° C. [0213] 1H NMR (CDCl3, ppm): 7.96 (D, 1H, J-6.9 Hz), 7.79 (D, 1H, J=6.0 Hz), 7.63 (M, 2H), 4.79 (M, 1H), 4.74 (S, 1H), 4.63 (S, 1H), 2.44 (M, 1H), 1.74 (S, 3H), 1.46, 1.08 1.00, 0.93, 0.91, 0.84 (S, 6×3H), 2.1-0.7 (Complex, 25H). 13C NMR (CDCl3, ppm): 172.05, 168.19, 151.29, 133.74, 132.25, 131.23, 130.79, 130.35, 129.37, 109.73, 83.59, 55.91, 50.73, 48.67, 48.37, 43.37, 43.21, 41.24, 40.37, 38.81, 38.43, 37.48, 35.94, 34.59, 30.21, 28.40, 27.81, 25.47, 23.51, 21.35, 19.66, 18.56, 18.37, 16.99, 16.51, 16.35, 14.91.
  • Example 5 Lupeol-3-succinate
  • [0214]
    Figure US20040097436A1-20040520-C00019
  • Lupeol-3-succinate [0215]
  • C[0216] 34H54O4
  • Exact Mass: 526.40 [0217]
  • Mol. Wt.: 526.79 [0218]
  • C, 77.52; H, 10.33; O, 12.15 [0219]
  • Place Lupeol 100 mg (1 equivalence) and succinic anhydride 0.070 g (3 equivalence) with imidazole 0.016 g (1 equivalence) in a 25 mL flask. Add dried dichloromethane 10 mL, then reflux for 48 hours. After the reaction is done, add sodium bicarbonate saturated water solution 10 mL, separate the organic part, and extract the water phase with dichloromethane (3×5 mL). Then use 3% HCl (3×10 mL) to wash the organic part, which is followed by drying with sodium sulfate (anhy.). Evaporating the solvent gives a white powder, which is stirred with 3% HCl 15 mL overnight, which is followed by filtration and drying in the oven. 0.12 g white powder is obtained with 97.6% yield. M.P.: 224.7-226.3° C. [0220] 1H NMR; 4.69 (S, 1H), 4.57 (S, 1H) 4.501 (M, 1H), 2.66 (M, 4H), 2.39 (M, 1H), 1.68 (S, 3H), 1.36, 1.03, 0.94, 0.85, 0.83, 0.79 (S, 6×3H), 1.8-0.7 (Complex, 25H), 13C NMR (CDCl3, ppm): 174.13, 168.54, 147.54, 105.94, 78.14, 51.94, 46.87, 44, 83, 44358, 39.56, 39.39, 37.40, 36.57, 34.91, 34.59, 34.41, 33.62, 32.13, 30.75, 26.39, 26.00, 25.72, 24.47, 23.99, 21.64, 20.21, 17.51, 15.86, 14.75, 14.58, 13.09, 12.74, 12.54, 11.09.
  • Example 6 3-Allobetulon-1-en-2-succinate
  • [0221]
    Figure US20040097436A1-20040520-C00020
  • 3-Allobetulon-1-en-2-succinate [0222]
  • C[0223] 34H50O6
  • Exact Mass: 554.36 [0224]
  • Mol. Wt.: 554.76 [0225]
  • C, 73.61; H, 9.08; O, 17.30 [0226]
  • Place 0.5 g 3-Allobetulon-1-en-2-ol (1 equivalent) and 0.33 g succinic anhydride (3 equivalents) with 0.13 g 4-(dimethylamino)-pyridine (1 equivalent) in a 25 mL flask. Add 10 mL acetonitrile and reflux for 48 hours, which is followed by adding 15 mL chloroform. Use 10 mL 3% HCl to wash the organic part three times, which is followed by drying with sodium sulfate (anhy.). Evaporating the solvent gives 0.55 g crude product. Use silica gel column to separate the crude product with solvent hexane: diethyl ether (3:1), which results in 0.303 g white amorphous solid with yield 49.7%. M.P.: 178.1-180.4° C. IR (cm[0227] −1); 2944.6, 2866.3, 1764.8, 1695.4, 1139.5; 1H NMR (CDCl3, ppm): 6.83 (S, 1H) 3.80 (D, 1H, J=7.8 Hz), 3.59 (S 1H), 3.49 (D, 1H, J=7.8 Hz), 2.82 (M 4H), 1.19, 1.17, 1.13, 1.05, 0.91, 0.82 (all S, 6×3H), 1.8-0.8 (Complex, 23H); 13C NMR (CDCl3, ppm): 198.10, 176.47, 170.86, 145.43, 143.16, 88.23, 71.52, 53.44, 46.99, 45.82, 45.40, 41.82, 41.84, 41.37, 40.07, 36.98, 36.58, 34.57, 33.54, 33.00, 29.10, 28.89, 28.79, 28.21, 26.66, 26.51, 24.89, 21.67, 20.52, 19.26, 16.49, 13.74.
  • Example 7 Allobetulin-3-diglycolate
  • [0228]
    Figure US20040097436A1-20040520-C00021
  • Allobetulin-3-diglycolate [0229]
  • m=0.300 g [0230]
  • C[0231] 34H54O6
  • Exact Mass: 558.39 [0232]
  • Mol. Wt.: 558.79 [0233]
  • C, 73.08; H, 9.74; O, 17.18 [0234]
  • In 25-mL flask, stir diglycolic anhydride 0.39 g and 0.5 g allobetulin in 15 mL CHCl[0235] 3. Then reflux for 24 hours. Add 10 mL saturated NaHCO3, shake gently. Then separate the organic part, use the CHCl3 (2×5 ml) to wash, and combine the organic parts. Use 3% HCl (10 ml) and water (2×10 ml) to wash it. Then use Na2SO4 (anhy.) to dry the organic part. Evaporating the solvent yields 0.57 g of white granular solid with yield 90.2%. M.P.: 285.2 (decompose). IR (KBr): 2964.07, 1753.33, 1223.67, 1110.16 cm−1; 1H NMR (CDCl3); δ 4.64 (DD, 1H), 4.32 (S, 4H), 3.66 (D, 1H, J=9 Hz), 3.54 (S, 1H), 3.46 (D, 1H, J=9 Hz), 0.97, 0.926, 0.891, 0.866, 0.852, 0.828, 0.796 (all S, 7×3H), 1.1-1.9 (complex CH—, CH2, 24H); 13C NMR (CDCl3): δ 171.28, 88.342, 83.431, 71.597, 69.498, 55.872, 51.339, 47.164, 41.837, 41.094, 40.985, 38.886, 38.289, 37.509, 37.079, 36.627, 34.478, 34.157, 33.057, 29.166, 28.408, 26.775, 26.601, 24.917, 24.072, 21.391, 18.476, 16.916, 16.064, 13.87.
  • Example 8 Allobetulin-3-glutarate
  • [0236]
    Figure US20040097436A1-20040520-C00022
  • Allobetulin-3-glutarate [0237]
  • C[0238] 35H56O5
  • Exact Mass: 556.41 [0239]
  • Mol. Wt.: 556.82 [0240]
  • C, 75.50; H, 10.14; O, 14.37 [0241]
  • Place 1 g Allobetulin (1 equivalent) and 0.52 g glutaric anhydride (2 equivalents) with imidazole 0.92 g (6 equivalence) in a 15 mL flask. Add 4.5 mL 1-methyl-2-pyrrolidinone and stir for 48 hours at 70° C. Pour the reaction mixture into 150 mL water. Adjust the pH to around 2. Stir for 3-4 hours and all the chunks should be broken into small particles. After filtration, dry the crude product in the oven. Crystalizing the crude product with chloroform and hexane yields 1.11 g of white amorphous product with yield 88.1%. M.P.: 283.2-284.9° C. IR (cm[0242] −1): 2948.9, 1724.7, 1458.9, 1281.8, 1217.4; 1H NMR (CDCl3, ppm): 4.50 (M, 1H), 3.80 (D, 1H, J=8.1 Hz), 3.55 (S, 1H), 3.46 (D, 1H, J=7.8 Hz), 2.46 (M, 4H), 1.99 (M, 2H), 0.98, 0.93, 0.92, 0.87, 0.84, 0.80 (all S, 6×3H), 1.8-0.8 (Complex, 28H); 13C NMR (CDCl3, ppm): 177.86, 173.08, 88.34, 81.44, 71.60, 55.92, 51.35, 47.18, 41.84, 41.09, 40.99, 38.93, 38.22, 37.53, 37.09, 36.63, 34.49, 34.20, 34.06, 33.31, 33.06, 29.17, 28.36, 26.79, 26.62, 24.92, 24.10, 21.38, 20.43, 18.51, 16.95, 16.07, 13.87.
  • Example 9 Allobetulin-3-phthalate
  • [0243]
    Figure US20040097436A1-20040520-C00023
  • Allobetulin-3-phthalate [0244]
  • m=0.300 g [0245]
  • C[0246] 38H54O5
  • Exact Mass: 590.40 [0247]
  • Mol. Wt.: 590.83 [0248]
  • C, 77.25; H, 9.21; O, 13.54 [0249]
  • In 25-ml flask, stir phthalic anhydride 0.20 g and imidazole 0.38 g in 10 ml CH[0250] 2Cl2, add the 0.5 g Allobetulin into the flask, and then reflux for 6 hours. Add 10 ml saturated sodium bicarbonate water solution into the flask, dissolve the solid, separate the organic part, use the CH2Cl2 (3×5 ml) wash and combine the organic parts. Use 3% HCl (3×10 ml) wash again. Use Na2SO4 (anhy.) to dry the organic part. Evaporate the solvent, get white solid 0.60 g with yield 89.6%. M.P.: 252.3-253.9° C.; IR (KBr): 2948.90, 2868.36, 1724.74, 1660.31, 1458.97, 1289.84, 1136.82, 1072.39, 975.75 cm−1; 1H NMR (CDCl3): δ 7.91 (D, J=6.6 Hz, 1H), 7.73 (D, J=6.9 Hz, 1H), 7.58 (M, 2H), 4.78 (M, 1H), 3.80 (D, 1H, J=7.8 Hz), 3.62 (S, 1H), 3.48 (D, J=7.8 Hz, 1H), 2.0-0.8 (complex, 45H); 13C NMR (CDCl3): 166.47, 163.55, 129.22, 127.32, 126.21, 125.98, 125.44, 124.28, 83.47, 78.42, 66.75, 51.23, 46.53, 42.31, 37.02, 36.25, 36.16, 34.15, 33.60, 32.72, 32.24, 31.77, 29.66, 29.37, 28.24, 24.31, 23.57, 21.96, 21.77, 20.08, 18.62, 16.60, 13.67, 12.19, 12.12, 11.26, 9.06.
  • Example 10 Allobetulin-3-succinate
  • [0251]
    Figure US20040097436A1-20040520-C00024
  • Allobetulin-3-succinate [0252]
  • m=0.300 g [0253]
  • C[0254] 34H54O5
  • Exact Mass: 542.40 [0255]
  • Mol. Wt.: 542.79 [0256]
  • C, 75.23; H, 10.03; O, 14.74 [0257]
  • In 25-ml flask, stir succinic anhydride 0.23 g and imidazole 0.46 g in 15 ml CH[0258] 2CH2, add 0.5 g allobetulin into the flask, and then reflux for 24 hours. Add 10 ml saturated sodium bicarbonate to dissolve the solid, then separate the organic part, use CH2Cl2 (2×5 ml) to wash and combine the organic parts. Use 3% HCl (2×10 ml) to wash the organic part. Use Sodium sulfate (anhy.) to dry the organic part. Evaporating the solvent results in a white granular solid. Stir the crude product in 3% HCl for 12 hours, after filtration, which gives 0.48 g of a white solid, with yield 78.7%. M.P.: (decomp.) 258.1-259.5° C.; IR (KBr): 2940.85, 2868.36, 1732.79, 1450.91, 1386.49, 1225.41, 1169.04 cm−1; 1H NMR (CDCl3): δ 4.52 (M, 1H), 3.78 (D, J=7.5 Hz, 1H), 3.55 (S, 1H), 3.45 (D, J=7.5 Hz, 1H), 2.65 (M, 4H), 0.76, 0.78, 0.84, 0.86, 0.90, 0.92, 1.0 (all S, 7×3H), 1.1-1.9 (complex, 24H); 13C NMR (CDCl3): 172.78, 167.44, 83.50, 77.00, 66.73, 51.10, 46.50, 42.31, 36.99, 36.14, 34.08, 33.38, 32.67, 32.23, 31.77, 29.62, 29.35, 28.21, 24.93, 24.56, 24.32, 23.41, 21.94, 21.76, 20.08, 19.14, 16.54, 13.65, 12.07, 11.22, 9.04.
  • Example 11 Betulin-3,28-didiglycolate
  • [0259]
    Figure US20040097436A1-20040520-C00025
  • Betulin-3,28-didiglycolate [0260]
  • m=0.200 g [0261]
  • C[0262] 38H58O10
  • Exact Mass: 674.40 [0263]
  • Mol. Wt.: 674.86 [0264]
  • C, 67.63; H, 8.66; O, 23.71 [0265]
  • In 15-ml flask, stir diglycolic anhydride 0.78 g and imidazole 0.92 g in 4.5ml 1-methyl-2-pyrrolidinone at 70° C. After they dissolve add 1 g Betulin. Stir for 24 hours. Pour mixture slowly into 180 ml water, adjust the pH to 2, stir the water solution until all the precipitate forms small granules. After the filtration, use 1% HCl, water to wash the product. Drying gives 1.45 g granular product (little brown color) with yield 94.8%. M.P. (decomp.) 137.8-139.2° C.; IR (KBr): 2961.07, 1747.02, 1220.45, 1144.87 cm[0266] −1, 1H NMR (CDCl3): δ 4.71 (S, 1H), 4.61 (complex, 2H), 4.2-4.45 (complex, 9H), 3.96 (D, J-11.4 Hz), 2.45 (M, 1H), 1.70 (S, 3H), 0.83, 0.85, 0.97, 1.04, (S, 4×3H), 1.05-2.10 (complex, 28H); 13C NMR (CDCl3): 168.46, 168.29, 166.50, 166.17, 145.34, 105.65, 78.48, 64.66, 64.39, 64.28, 59.60, 50.83, 45.75, 44.28, 43.20, 41.94, 38.23, 36.40, 33.83, 33.43, 33.14, 32.56, 29.99, 29.58, 25.16, 23.57, 22.52, 20.61, 19.23, 16.31, 14.62, 13.66, 12.02, 11.68, 11.54, 10.27.
  • Example 12 Betulin-28-diglycolate
  • [0267]
    Figure US20040097436A1-20040520-C00026
  • Betulin-28-diglycolate [0268]
  • C[0269] 37H54O6
  • Exact Mass: 558.39 [0270]
  • Mol. Wt.: 558.79 [0271]
  • C, 73.08; H, 9.74; O, 17.18 [0272]
  • Place Betulin 0.5 g (1 equivalent) and diglycolic anhydride 0.14 g (1.02 equivalents) with imidazole 0.31 g (4 equivalents) in a 15 mL flask. Add 4 mL 1-methyl-2-pyrrolidinone and stir 48 hours at room temperature. Pour the mixture into 150 mL water, which is followed by adjusting pH to around 2. Stir for 2-3 hours. All the chunks should be broken to small particles. After filtration, dry the crude product in the oven, which is followed by passing through a silica gel column with hexane: diethyl ether (3:1). This yielded 0.43 g white prizm solid with yield 68.3%. M.P.: 219.2-220.2° C. IR (cm[0273] −1): 3454.5, 2941.1, 1759.5, 1729.44, 1216.3, 1136.8, 1H NMR (CDCl3, ppm): 4.74 (S, 1H), 4.65 (S, 1H), 4.48 (D, 1H, J=11.1 Hz), 4.33 (S, 4 h), 4.05 (D, 1H, J=11.1 Hz), 3.27 (M, 1H), 2.49 (M, 1H), 1.73 (S, 3H), 1.08, 1.02, 1.01, 0.87, 0.81 (all S, 5×3H), 2.2-0.6 (Complex, 25H); 13C NMR (CDCl3, ppm): 172.16, 171.55, 150.19, 110.46, 79.44, 69.60, 69.32, 64.58, 55.64, 50.69, 49.15, 48.02, 46.79, 43.06, 41.23, 39.21, 39.05, 38.01, 37.50, 34.83, 34.53, 30.01, 29.82, 28.34, 27.68, 27.36, 25.52, 21.11, 19.49, 18.64, 16.47, 16.39, 15.74, 15.14.
  • Example 13 Betulin-3,28-diglutarate
  • [0274]
    Figure US20040097436A1-20040520-C00027
  • Betulin-3,28-diglutarate [0275]
  • m=0.300 g [0276]
  • C[0277] 40H62O8
  • Exact Mass: 670.44 [0278]
  • Mol. Wt.: 670.92 [0279]
  • C, 71.61; H, 9.31; O, 19.08 [0280]
  • In 15-ml flask, stir glutaric anhydride 1.29 g and imidazole 1.54 g in 4.5 ml 1-methyl-2-pyrrolidinone at 70° C. After they dissolve add 1 g betulin. Stir for 48 hours. Pour mixture slowly into 180 ml water, adjust the pH to 2, and stir the water solution until all the precipitate forms small granules. After the filtration, use 1% HCl in water to wash the product. Drying results in 1.22 g gray solid powder with yield 80.3%. M.P. (decomp.): 104.5-106.2° C.; IR (KBr): 2956.95, 2876.42, 1732.79, 1458.97, 1386.49, 1201.25, 991.85 cm[0281] −1; 1H NMR (CDCl3): δ 4.69 (S, 1H), 4.49 (S,1H), 4.50 (M, 1H), 4.29 (D, 1H, J=10.5 Hz), 3.85 (D, 1H, J=11.1 Hz), 2.42 (M, 9H), 1.98 (M, 5H),1.68 (S, 3H), 0.75-1.9 (complex, 39H); 13C NMR (CDCl3): 178.947, 173.693, 173.059, 150.463, 110.297, 81.478, 63.217, 55.712, 50.618, 49.132, 48.082, 46.741, 43.054, 41.247, 38.711, 38.194, 37.924, 37.414, 34.937, 34.449, 34.026, 33.669, 33.370, 30.120, 29.916, 28.371, 27.388, 25.493, 24.087, 21.157, 20.385, 20.254, 19.481, 18.519, 16.938, 16.516, 16.392, 15.109.
  • Example 14 Betulin-28-glutarate
  • [0282]
    Figure US20040097436A1-20040520-C00028
  • Betulin-28-glutarate [0283]
  • C[0284] 35H56O5
  • Exact Mass: 556.41 [0285]
  • Mol Wt.: 556.82 [0286]
  • C, 75.50; H, 10.14; O, 14.37 [0287]
  • Place 1 g of Betulin (1 equivalent) and 0.271 g glutaric anhydride (1.05 equivalents) with 0.615 g imidazole (4 equivalents) in a 25 mL flask, add 4 mL 1-methyl-2-pyrrolidinone and stir for 48 hours at room temperature. Pour the mixture in 150 mL water, while stirring. Then adjust pH to around 3. Break the big chunks to small particles, which is followed by filtration and drying in the oven. The crude products are passed through the silica gel column with diethyl ether: hexane (1:3). This results in 0.765 g white prism solid with a yield of 60.7%. M.P.: 204.3-206.1° C. IR (cm[0288] −1): 3438.7, 2962.4, 2870.5, 1741.7, 1717.1, 1463.0, 1395.2; 1H NMR (CDCl3, ppm): 4.73 (S, 1H), 4.64 (S, 1H), 4.35 (D, 1H, J=11.1 Hz), 3.93 (D, 1H, J=11.1 Hz), 3.25 (M, 1H), 2.50 (M, 5H), 1.73 (S, 3H), 1.08, 1.02, 0.87, 0.81 (all S, 4×3H), 2.2-0.8 (Complex, 30H); 13C NMR (CDCl3, ppm): 177.72, 173.67, 150.49, 110.25, 79.39, 63.202, 55.65, 50.72, 49.15, 48.06, 46.75, 43.06, 41.23, 39.22, 39.05, 37.94, 37.51, 34.94, 33.68, 33.16, 30.14, 29.94, 28.35, 27.73, 27.40, 25.55, 21.14, 20.27, 19.51, 18.65, 16.47, 16.40, 15.74, 15.14.
  • Example 15 Betulin-3,28-dimaleate
  • [0289]
    Figure US20040097436A1-20040520-C00029
  • Betulin-3,28-dimaleate [0290]
  • m=0.300 g [0291]
  • C[0292] 38H54O8
  • Exact Mass: 638.38 [0293]
  • Mol. Wt.: 638.83 [0294]
  • C, 71.44; H, 8.52; O, 20.04 [0295]
  • In 50-ml flask, stir maleic anhydride 11.09 g and Betulin 5 g in 20 ml 1-methyl-2-pyrrolidinone at 70° C. for 48 hours. Pour the mixture slowly into 800 ml water, adjust the pH to 3, and stir the water solution until all the precipitation forms small granules. After the filtration, use 1% HCl, in water to wash the product. Drying gives 6.50 g gray solid granules with yield 90.1%. M.P.: 181.4-182.9° C.; IR (KBr): 2952.27, 1738.94, 1700.43, 1635.34, 1239.03, 994, 826 cm[0296] −1; 1H NMR (CDCl3): 6.55-6.40 (M, 4H), 4.76-4.67 (complex, 3H), 4.56 (D, J=11.1 Hz, 1H), 4.09 (D, J=10.5 Hz, 1H), 2.45 (M, 1H), 1.70 (S, 3H), 0.78, 0.81, 0.90, 1.02, 1.10 (all S, 5×3H), 1.12-2.1 (complex, 24H); 13C NMR (CDCl3): 163.80, 163.41, 159.92, 159.76, 145.10, 132.64, 132.20, 125.13, 124.76, 105.80, 80.56, 61.43, 50.83, 45.73, 44.30, 43.19, 41.94, 38.26, 36.40, 34.38, 33.80, 33.45, 33.23, 32.57, 29.90, 29.55, 25.04, 24.92, 23.50, 22.48, 20.59, 18.89, 16.30, 14.63, 13.63, 11.97, 11.68, 11.55, 10.90, 10.30.
  • Example 16 Betulin-28-maleate
  • [0297]
    Figure US20040097436A1-20040520-C00030
  • Betulin-28-maleate [0298]
  • m=0.300 g [0299]
  • C[0300] 34H52O5
  • Exact Mass: 540.38 [0301]
  • Mol. Wt.: 540.77 [0302]
  • C, 75.51; H, 9.69; O, 14.79 [0303]
  • In 500-ml flask, stir maleic anhydride 3.33 g and 10 g Betulin in 200 ml CHCl[0304] 3. Reflux for 40 hours. Add 50 mL 3% HCl, separate the organic part, use CHCl3 (3×20 mL) to wash the aqueous phase, and combine the organic parts. Use 3% HCl (2×50 mL) to wash the organic phase, which is followed by using Na2SO4 (anhydrous) to dry organic part. After evaporating the solvent, use THF-hexane to crystalize the crude product. This gives 9.2 g white product with yield 75.2%, M.P.: 242.5-243.6° C.; IR (KBr): 3416.01, 2948.90, 2868.36, 1716.69, 1652.26, 1265.68, 1233.47 cm−1; 1H NMR(CDCl3): δ 6.5 (Q, 2H), 4.78 (S, 1H), 4.68 (S, 1H), 4.56 (D J=11.1 Hz, 1H), 4.12 (D, J=11.1 Hz, 1H), 3.26 (M, 1H), 2.50 (M, 1H), 1.76 (S, 3H), 0.84, 0.90, 1.05, 1.06, 1.10 (S, 5×3H), 2.1-0.8 (complex, 25H); 13C NMR (CDCl3): 163.901, 159.57, 145.15, 132.58, 124.62, 105.75, 74.52, 61.44, 50.81, 45.85, 44.35, 43.18, 41.96, 38.25, 36.40, 34.39, 34.23, 33.27, 32.67, 29.91, 29.69, 25.09, 24.94, 23.51, 22.88, 22.50, 20.68, 16.27, 14.65, 13.80, 11.64, 11.56, 10.90, 10.33.
  • Example 17 Betulin-3,28-diphthalate
  • [0305]
    Figure US20040097436A1-20040520-C00031
  • Betulin-3,28-diphthalate [0306]
  • m=0.300 g [0307]
  • C[0308] 46H58O8
  • Exact Mass: 738.41 [0309]
  • Mol. Wt.: 738.95 [0310]
  • C, 74.77; H, 7.91; O, 17.32 [0311]
  • In 50-ml flask, stir phthalic anhydride 8.37 g and imidazole 7.69 g in 20 ml 1-methyl-1-pyrrolidinone at 70° C. After they dissolve, add 5 g betulin. Stir for 48 hours. Pour mixture slowly into 800 ml water, adjust the pH to 2, and stir the water solution until all the precipitate forms small granules. After the filtration, use 1% HCl in water to wash the product. Drying gives 7.59 g granules (light yellow color) with yield 90.8%. M.P. (decomp.) 166.8-168.6° C.; IR (KBr): 2956.95, 2876.42, 1716.69, 1394.54, 1281.79, 1128.77, 1088.50, 991.85, 742.19 cm[0312] −1; 1H NMR (CDCl3): δ 7.87 (M 2H), 7.77 (M, 2H), 7.58 (M, 4H), 4.76-4.53 (complex, 4H), 4.08 (D, J=10.2 Hz, 1H), 2.50 (M, 1H), 1.68 (S, 3H), 0.82, 0.84, 0.90, 1.02, 1.08 (all S, 5×3H), 1.1-2.2 (complex, 24H); 13C NMR (CDCl3): 168.57, 168.33, 163.68, 162.99, 145.58, 128.79, 128.23, 127.37, 126.56, 126.39, 126.32, 126.19, 125.22, 125.08, 124.69, 124.50, 105.47, 78.49, 60.12, 51.04, 45.80, 44.46, 43.36, 42.09, 39.22, 38.27, 36.40, 33.99, 33.56, 33.24, 32.62, 29.96, 29.53, 25.12, 23.55, 22.58, 20.68, 18.72, 16.42, 14.62, 13.66, 12.20, 11.72, 11.56, 10.48.
  • Example 18 Allobetulin, oleanan-3β-ol-28 19-β-ether
  • [0313]
    Figure US20040097436A1-20040520-C00032
  • In 100-ml flask stir 2 g of Betulin in 50 ml of CH[0314] 2Cl2 at 0° C. Add 5 ml of 99% CF3COOH and stir for 30 minutes. Pour reaction mixture in 100 ml of cracked ice and separate the organic part. Extract with CH2Cl2 (3×10 ml) and wash combined organic extracts with conc. NaHCO3 (2×20 ml) and water (2×20 ml), and dry the extract over Na2SO4 (anh.). Evaporation of solvent gives 1.98 g of Allobetulin, which was recrystallized from hexane-dichloromethane to yield white needles mp. 268-269° C. [lit. 265-268], IR (KBr) 3448.5, 2941.5, 2866.6, 1780.7, 1456.6, 1384.4, 1168.9, 1035.0, cm−1; 1H NMR (CDCl3) d 3.75 (D, J=10.3 Hz, 1H, 28-H), 3.51 (S, 1-H, 19-H), 3.41 (D, J=10.3 Hz, 1H, 28-H), 3.18 (DD, 1H, 3-H), 0.74, 0.76, 0.81, 0.88, 0.89, 0.94, 0.94 (all S, 7×3H, 27-, 23-, 24-, 25-, 26-, 29-, 30-Me), 1.01-1.74 (complex CH—, CH2, 25 H,); 13C NMR (CDCl3) d 88.41, 79.38, 71.49, 55.77, 51.35, 47.07, 41.78, 40.99, 40.88, 40.87, 39.16, 37.52, 36.95, 36.51, 34.40, 34.18, 32.96, 29.08, 28.27, 27.57, 26.72, 26.72, 26.50, 24.82, 21.26, 18.54, 16.79, 15.96, 15.72, 13.82; MS (EI) 442, 424, 411, 371, 355, 303, 273, 257, 245, 231, 220, 207, 203, 189, 177, 162, 149,135, 121,107.
  • Example 19 Allobetulinlactone oleanan-3β-ol-28,19-β-lactone
  • [0315]
    Figure US20040097436A1-20040520-C00033
  • In 100-ml flask boil 2 g of Allobetulin-3-trifluoroacetyl lactone in 50 ml of CH[0316] 3OH in presence of 0.723 g KOH for 4 hours. Evaporate methanol and dilute with 100 mL of cold water. Filter the precipitate and wash with water (3×50 mL). Dry crystals in oven at 110° C. and recrystallize from hexane-dichloromethane to yield white needles. mp. 316.3-317.6° C., IR (KBr) 3495, 2940, 2866, 1759, 1447, 1388, 1153, 1118, 967, 923 cm−1; 1H NMR (CDCl3) d 3.97 (S, 1H, 19H), 3.22 (DD, 1H, 3H), 1.057, 1.000, 0.987, 0.942, 0.903, 0.87, 0.791 (all S, 7×3H, 23-, 24-, 25-, 26-, 27-, 29-, 30-Me), 1.1-1.9 (complex CH—, CH2—, 24H); 13C NMR (CDCl3) d 180.207, 86.316, 79.174, 55.791, 51.528, 47.01, 46.413, 40.853, 40.212, 39.242, 39.177, 37.552, 36.313, 34.018, 33.843, 32.619, 32.232, 29.055, 28.254, 28.188, 27.642, 26.826, 25.842, 24.261, 21.178, 18.46, 16.85, 15.822, 15.669, 13.964; MS (EI) 456, 438, 423, 395, 356, 329, 261, 234, 206, 189, 175, 161, 147, 135, 121, 107, 95, 81, 69, 55, 43.
  • Example 20 Allobetulinlactone-3-acetate oleanan-28,19-β-lactone-3-acetate
  • [0317]
    Figure US20040097436A1-20040520-C00034
  • In 100-ml flask stir 2 g of 3-O-acetyl-betulin in 50 ml of CH[0318] 2Cl2 at 0° C. Add 10 ml of 99% proof CF3COOH stir for 10 minutes and after that add 2.2 g of powdered NaBrO3. Stir the mixture for 6 hours and then pour in 100 ml of cracked ice and separate organic part. Extract with CH2Cl2 (3×10 ml) and wash combined organic extracts with 10% aqueous NaHSO3 (2×30 ml), 5% aqueous NaHCO3 (2×30 ml) and water (2×20 ml), and dry the extract over Na2SO4 (anh.). Evaporation of solvent gives 2.08 g of 3-O-acetyl allobetulin-lactone, which was recrystallized from hexane-dichloromethane to yield white needles. mp. 312.5-315.4° C. (dec.), IR (KBr) 2943, 2878, 1761, 1729, 1502, 1486, 1446, 1374, 1252 cm−1; 1H NMR (CDCl3) d 4.50 (DD, 1H, 3H), 3.94 (S, 1H, 19H), 2.03 (S, 3H, Ac-Me), 1.04, 0.97, 0.95, 0.8, 0.8, 0.79, 0.78 (all S, 7×3H, 23-, 24-, 24-, 25-, 26-, 29-, 30-Me), 1.02-1.79 (complex CH—, CH2—, 23H); 13C NMR (CDCl3) d 13.899, 15.779, 16.741, 16.879, 18.307, 21.164, 21.601, 23.896, 24.210, 26.745, 25.784, 28.158, 28.159, 29.004, 32.181, 32.568, 33.792, 33.916, 36.284, 37.428, 38.055, 38.878, 40.175, 46.420, 40.831, 46.959, 51.419, 55.835, 180.352, 81.244, 86.381, 171.579; MS (EI) 482, 438, 424, 395, 356, 327, 281, 253, 207, 189, 174, 162, 147, 135, 121,43.
  • Example 21 Allobetulinlactone-3-phosphate oleanan-28,19-β-lactone-3-phosphate
  • [0319]
    Figure US20040097436A1-20040520-C00035
  • In 100 mL round bottom flask boil a solution of allobetulin-3-phosphodichloride in 50 mL of dioxane and 1 mL of water for 18 hours. Dilute with cold water (50 mL) and filter white precipitate. Wash on filter with water (3×30 mL). Dry in oven (temperature not higher than 110° C.) to give 3.12 g of white crystalline compound mp. 226.7-230.1° C. (dec)[lit. ***], IR (KBr) 3414, 2945, 2868, 1760, 167, 1449, 1384, 1524, 1213, 1068, 1025, 967, 495 cm[0320] −1; 1H NMR (CDCl3/DMSOd6=1:1) d 5.64 (S, 2H, (OH)2) 3.94 (S, 1H, 19H), 3.81 (M, 1H, 3-H), 1.001, 0.98, 0.98, 0.89, 0.89, 0.87, 0.78 (all S, 7×3H, 23-, 24-, 25-, 26-, 27-, 29-, 30-Me), 1.05-1.95 (complex CH—, CH2—, 23H); 13C NMR (CDCl3/DMSOd6) d 177.852, 84,195, 82.504, 53.984, 49.510, 44.897, 44.431, 38.995, 38.405, 38.405, 37.275, 37.181, 35.556, 34.608, 32.065, 30.928, 30.243, 27.38, 26.637, 26.345, 24.851, 24.057, 23.758, 22.381, 19.408, 16.712, 15.174, 14.817, 14.059, 12.296; 31P NMR (D3PO4 85% in D2O) d-0.719.
  • Example 22 Allobetulin-3-hydroxy-3-aminomethyl 3-aminomethyl-3-hydroxy-28,19-β-epoxy-oleanan
  • [0321]
    Figure US20040097436A1-20040520-C00036
  • In 25 mL round bottom flask boil the mixture of allobetulon (0.86 g, 1.955 mmol), ZnI[0322] 2 (20 mg, 0.063 mmol) and tret-butyldimethylsilylcyanide (0.420 g, 3.78 mmol) in 15 mL of Toluene for 24 hours. Add the above mentioned mixture to a suspension of LiAlH4 (0.37 g, 10 mmol) in 30 mL of THF drop wise and boil for 2 hours. Next, add 0.5 mL of concentrated KOH, dilute with 30 mL of THF and filter with diatomaceous earth. Dry over sodium sulfate and bubble HCl gas through the THF solution and filter the white precipitate (0.98 g). Dissolve the crystals in 50 mL of chloroform and wash with 1% NaHCO3 until neutral reaction of universal paper indicator. Separate organic part and dry over sodium sulfate. Evaporation of solvent gives 0.89 g (96% yield) of white crystalline compound mp. 222.0-224.3° C., IR (KBr) 3414, 2939, 2868, 1617, 1461, 1384, 1036 cm−1; 1H NMR (CDCl3) d 3.67 (D, 1H, 28H, J=7.5 Hz), 3.521 (S, 1H, 19H), 3.437 (D, 1H, 28H, J=7.5 Hz), 2.95 (D, 1H, 31H, J=13.2 Hz), 2.757 (D, 1H, 31H, J=13.2 Hz), 2.523 (S, 3H, OH+NH2), 0.972, 0.926, 0.911, 0.904, 0.894, 0.824, 0.798 (all S, 7×3H, 23-, 24-, 25-, 26-, 27-, 29-, 30-Me), 1.01-1.79 (complex CH—, CH2—, 24H); 13C NMR (CDCl3) d 88.13, 75.174, 71.428, 62.517, 53.554, 51.703, 47.018, 43.265, 41.669, 40.911, 40.882, 40.882, 37.683, 37.596, 36.933, 36.459, 34.309, 32.903, 30.265, 29.048, 27.416, 26.643, 26.454, 24.771, 24.166, 21.171, 19.947, 18.905, 17.076, 15.961, 13.811.
  • Example 22 Allobetulin-3-phosphate 28,19-β-epoxy-oleanan-3-phosphate
  • [0323]
    Figure US20040097436A1-20040520-C00037
  • In 100 mL round bottom flask boil a solution of Allobetulin-3-phosphodichloride in 50 mL of dioxane and 1 mL of water for 18 hours. Dilute with cold water (50 mL) and filter white precipitate. Wash on filter with water (3×30 mL). Dry in oven (temperature not higher than 110° C.) to give 3.12 g of white crystalline compound mp. 167.0-168.1° C. (dec), IR (KBr) 3469, 2947, 2868, 1775, 1467, 1388, 1221, 1169, 1022, 884, 585, 505, 481 cm[0324] −1; 1H NMR; 31P NMR (D3PO4 85% in D2O) d-0.684.
  • Example 23 Allobetulon oleanan-3-one-28,19-β-ether
  • [0325]
    Figure US20040097436A1-20040520-C00038
  • In 100-mL round bottom two neck flask place 11 mmol (1.397 g) (COCl)[0326] 2 in 25 ml of dry CH2Cl2 at −50-60° C. (i-Pr alcohol—dry ice bath) and with efficient stirring add 22 mmol (1.76 g) of dry DMSO in 25 ml of dry CH2Cl2 in drop wise in 3-5 minutes. Stir the mixture for additional 5 minutes and then add crystals of allobetulin (10 mmol, 4.43 g). Stand solution for 30-45 minutes and after adding with 25 mmol (2.53 g) of triethylamine, remove cold bath and let temperature to increase up to 10° C. Pour the mixture in 100 ml of cracked ice, extract with CH2Cl2 (3×20 ml) and wash combined organic extracts with water (5×10 ml), 5% HCl (2×10 ml), and H2O (2×10 ml). After drying over sodium sulfate solvent evaporation gives 4.4 g of crude compound, which after column chromatography (hexane:ether=80:20) gives 4.31 g of white crystals mp. 228.8-233.1° C. [lit. 230-235° C.], IR (KBr) 2949, 2859, 1774, 1702, 1457, 1382, 1167, 1034 cm−1; 1H NMR (CDCl3) d 3.74 (D, J=10.3 Hz, 1H, 28-H), 3.48 (S, 1-H, 19H), 3.39 (D, J=10.3 Hz, 1H, 28-H), 2.37 (M, 2H, 2-H,H), 1.85 (M, 1H, 19-H), 0.72, 0.81, 0.815, 0.91, 0.92, 0.99 (all S, 7×3H, 27-, 23-, 24-, 25-, 26-, 29-, 30-Me), 1.01-1.54 (complex CH—, CH2—, 25H); 13C NMR (CDCl3) d 218.08, 88.01, 71.39, 55.08, 50.55, 47.43, 46.92, 41.60, 40.91, 40.68, 39.97, 37.11, 36.88, 36.43, 34.41, 34.23, 33.33, 32.86, 29.00, 26.92, 26.60, 26.60, 26.40, 24.73, 21.68, 21.16, 19.79, 16.52, 15.68, 13.63; MS (EI) 440, 422, 411, 369, 355, 281, 220, 207, 205, 191, 177, 163, 149, 135, 121.
  • Example 24 Allobetulonlactone-1-ene-2-ol 2-hydroxy-olean-1,2-ene-3-one-28,19-β-lactone
  • [0327]
    Figure US20040097436A1-20040520-C00039
  • To a solution of Allobetulonlactone (1.0 g) in dry benzene-tert-butyl alcohol (1:1, 40 ml) was added a solution of potassium tert-butoxide (0.56 g) in tert-butyl (20 ml) and oxygen was bubbled into the stirred mixture for 3 hours. The mixture was acidified with 2.0 ml of glacial acetic acid and extracted with CH[0328] 2Cl2. After washing with water (2×15 ml), 5% aqueous NaHCO3 (2×30 ml) and water (30 ml), the extract was dried over Na2SO4 and evaporated to give crystals (m=0.983 g, 98%), which after chromatography on silica gel (hexane: ether=40:60) yields a white crystalline compound mp. 238.8-243.6° C., IR (KBr) 3451, 2944, 2864, 1764, 1663, 1642, 1450, 1405, 1384, 1234, 1055, 967 cm−1; 1H NMR (CDCl3) d 6.47 (S, 1H, 2-H), 6.07-5.85 (1H, OH), 3.96 (S, 1H, 19H), 1.207, 1.153, 1.109, 1.037, 0.98, 0.974, 0.877 (all S, 7×3H, 23-, 24-, 25-, 26-, 27-, 20-, 30-Me), 1.05-1.91 (complex CH—, CH2, 22H); 13C NMR (CDCl3) d 201.36, 180.025 144.217, 128.966, 86.192, 54.501, 46.879, 46.631, 46.376, 44.292, 41.654, 40.525, 38.936, 36.393, 33.836, 33.632, 32.568, 32.174, 29.034, 28.006, 27.365, 26.571, 25.784, 24.232, 21.841, 21.397, 20.923, 18.868, 16.282, 13.768, MS (EI) 468, 454, 441, 425, 407, 369, 340, 313, 303, 269, 259, 234, 215, 207, 189, 176, 165, 153, 151, 135, 128, 124, 108, 95, 78, 69, 55, 43.
  • Example 25 Allobetulon-1-ene-2-ol 2-hydroxy-28,19-β-epoxy-olean-1(2)-ene-3-one
  • [0329]
    Figure US20040097436A1-20040520-C00040
  • To a solution of allobetulon (1.8 g) in dry benzene-tert-butyl alcohol (1:1, 40 ml) was added a solution of potassium tert-butoxide (1.2 g) in tert-butyl (20 ml) and oxygen was bubbled into the stirred mixture for 1.5 hours. The mixture was acidified with 2.5 ml of glacial acetic acid and extracted with CH[0330] 2Cl2. After washing with water (2×15 ml), 5% aqueous NaHCO3 (2×30 ml) and water (30 ml), the extract was dried over Na2SO4 and evaporated to give crystals, which after chromatography on silica gel (hexane: ether=85:15) 1402, 1234, 1058, 1035 cm−1; 1H NMR (CDCl3) d 6.46 (S, 1H, 1-H), 5.9 (S, 1H, 2-OH), 3.75 (D, 1H, 28H), 3.52 (S, 1H, 19-H), 3.52 (S, 1H, 28H), 0.78, 0.91, 0.99, 1.01, 1.09, 1.13, 1.19 (all S, 7×3, 23-, 24-, 25-, 26-, 27-, 29-, 30-Me), 1.05-1.78 (complex CH—, CH2, 25H); 13C NMR (CDCl3) d 201.43, 144.202, 129.29, 88.16, 71.523, 54.49, 46.99, 44.3, 41.75, 41.312, 38.97, 36.98, 36.56, 34.53, 33.83, 32.97, 29.1, 27.41, 26.6, 26.52, 24.86, 21.89, 21.51, 20.87, 18.96, 16.5, 13.64; MS (EI) 454 383, 327, 281, 245, 215, 207, 191, 177, 151, 137, 136, 123, 109, 95, 81, 69, 55.
  • Example 26 Betulin lup-20(29)-ene-3,28-diol
  • [0331]
    Figure US20040097436A1-20040520-C00041
  • Isolation of Betulin
  • Betulin was isolated from paper birch ([0332] B. papyrifera) bark. Shredded, dry bark (500 g) has been extracted with chloroform on a Soxhlet apparatus for 10 hours. The extract was evaporated and then was left overnight at 5-7° C. Crystals were filtered and washed with hexane and then dried in oven to give 94.5 g of crude Betulin. Double crystallization from chloroform and then mixture of chloroform-isopropyl alcohol(4:1) gives 64-68 g of pure Betulin mp. 258-259° C. [lit. mp 256-261° C.]. IR (KBr) 3378, 2942, 2868, 1645, 1453, 1374, 1106, 1031, 880 cm−1; 1H NMR (CDCl3) d 4.68 (S, 1H, 29-H), 4.58 (S, 1H, 29-H), 3.8 (D, J=10.3 Hz, 1H, 28-H, 3.34 (D, J=10.3 Hz, 1H, 28-H), 3.18 (DD, 1H, 3-H), 2.38 (M, 1H, 19-H), 1.68 (S, 3H, 30-Me), 0.76, 0.82, 0.97, 0.98, 1.02 (all S, 5×3H, 27-, 23-, 24-, 25-, 26-Me), 1.01-2.4 (complex CH—, CH2, 25 H,); 13C NMR (CDCl3) d 151.249, 110.464, 79.736, 61.278, 56.017, 51.12, 49.48, 48.533, 48.534, 43.454, 41.647, 39.614, 39.432, 38.033, 37.894, 34.958, 34.725, 30.469, 29.901, 28.742, 28.123, 27.773, 25.929, 21.572, 19.845, 19.051, 16.879, 16.726, 16.136, 15.516; MS (EI) 442, 424, 411, 398, 393, 381, 288, 234, 207, 203, 189, 175, 161, 147, 135, 121, 107.
  • Example 27 Betulon-1-ene-2-ol lup-1(2),20(29)-diene-2,28-diol-3-one
  • [0333]
    Figure US20040097436A1-20040520-C00042
  • To a solution of betulin-28-acetate (1.0 g) in dry benzene-tert-butyl alcohol (1:1, 40 ml) was added a solution of potassium tert-butoxide (1.05 g) in tert-butanol (20 ml). Oxygen was bubbled into the stirred mixture for 1.5 hours. The mixture was acidified with 2.2 ml of glacial acetic acid and extracted with CH[0334] 2Cl2. After washing with water (2×15 ml), 5% aqueous NaHCO3 (2×30 ml) and water (30 ml), the extract was dried over Na2SO4 and evaporated to give crystals, which after chromatography on silica gel (hexane:ether=80:20) yielded a white crystalline compound mp. 167-170 (dec) ° C., IR (KBr) 3446, 2944, 2870, 1717, 1669, 1647, 1457, 1406, 1237, 1032, 882 cm−1; 1H NMR (CDCl3) d 6.43(S, 1H, 2-H), 6.12-5.81 (OH), 4.69 (S, 1H, 29H), 4.60 (S, 1H, 29H), 3.79 (DD, 1H, 28-H, J=10.7 Hz), 3.35 (DD, 1H, 28-H, J=10.7 Hz), 2.4 (M, 1H, 19-H), 1.69 (S, 3H, 30-Me), 1.203, 1.124, 1.105, 1.09, 0.976 (all S, 5×3H, 23-, 24-, 25-, 26-, 27-Me), 1.05-2.01 (complex CH—, CH2 22H); 13C NMR (CDCl3) d 201.513, 150.491, 144.188, 129.228, 110.209, 60.768, 54.217, 48.883, 48.045, 48.045, 45.844, 44.278, 43.309, 42.019, 38.893, 37.654, 34 244, 34.149, 29.974, 29.398, 27.409, 27.226, 25.332, 21.907, 21.353, 20.457, 19.364, 19.021, 16.755 114.941; MS (EI) 454, 438, 424, 381, 325, 302, 271, 229, 215, 189, 177, 161, 135,121,95, 81, 55.
  • Example 28 Betulin-3,28-diphosphaate Lup-20(29)-ene-3,28-diphosphate
  • [0335]
    Figure US20040097436A1-20040520-C00043
  • In 100 mL round bottom flask boil a solution of betulin-3,28-diphosphodichloride in 50 mL of dioxane and 1 mL of water for 18 hours. Dilute with cold water (50 mL) and filtrate white precipitate. Wash on filter with water (3×30 mL). Dry in oven (temperature not higher than 110° C.). [0336]
  • Example 29 Betulin-3,28-diphosphate Sodium Salt Lup-20(29)-ene-3,28-sodiumdiphosphate
  • [0337]
    Figure US20040097436A1-20040520-C00044
  • In 100 mL round bottom flask to a suspension of 1 g (1.66 mmol) of betulin-3,28-diphosphate in 40 mL of water a solution of 0.6 g of sodium bicarbonate in 40 ml of water was added dropwise to maintain pH<=7. Water was evaporated under reduced pressure and white precipitate was dried in vacuum. [0338]
  • Example 30 Betulinic Acid 3-hydroxy-lup-20(29)-ene-28-oic Acid
  • [0339]
    Figure US20040097436A1-20040520-C00045
  • Betulinic aldehyde (1.5 g) was dissolved in 45 ml of ethyl acetate and then was placed in a 100 ml heatable column. 0.6 ml of distilled water and 23 mg of ABIN was added to the solution. Oxygen has been bubbled through the mixture at 50-60° C. for 6 hours with periodic addition of ABIN (5 mg per hour). Evaporation of solvent and following crystallization from MeOH gives 1.42 g of white crystals mp. 288-291° C. [lit. 291-292], IR (KBr) 3449, 2941, 2869, 1686, 1639, 1451, 1376, 1235, 1186, 1043, 886 cm[0340] −1; 1H NMR (CDCl3), d 4.79 (S, 1H, 29 H), 4.65 (S, 1 H, 29H), 3.22 (DD, 1H. 3-H), 3.02 (T, 1 H, 19H), 1.66 (S, 3 H, 30-Me), 0.79, 0.83, 0.88, 1.0, 1.0 (all S, 5×3H, 23-, 24-, 25-, 26-, 27-Me), 1.05-2.24 (complex CH—, CH2, 25H); 13C NMR (CDCl3) d 180.403, 150.542, 109.86, 79.146, 56.433, 55.471, 50.64, 49.401, 47.025, 42.573, 40.824, 39.01, 38.842, 38.529, 37.348, 37.174, 34.456, 32.291, 30.688, 29.85, 28.138, 27.54, 25.631, 20.982, 19.518, 18.417, 16.282, 16.173, 15.495. 14.847; MS (EI) (after sililation) 518, 510, 487, 483, 471, 456, 428, 413, 393, 377, 353, 320, 306, 292, 257, 203, 189, 175, 148, 135, 129, 73.
  • Example 31 Lupeol monoglynol B, β-viscol, Fagarasterol lup-20(29)-ene-3β-ol
  • [0341]
    Figure US20040097436A1-20040520-C00046
  • Combined parts after Betulin crystallization and solvent evaporation were separated on silica gel (eluent hex: ether=10:1). After 150 ml solvent delay 20 fractions were collected. Fractions 1-7 contain mixture of lower terpenes, fractions 8-13 contained Lupeol mp 182.7-187.3° C., IR (KBr) 3380, 2920, 1450,1405, 1025, 940 cm[0342] −1; 1H NMR (CDCl3) d 4.69 (S, 1H, 29-H), 4.55 (S, 1H, 29-H), 3.18 (DD, 1H, 3-H), 2.35 (M, 1H, 19-H), 1.67 (S, 3H, 30-Me), 0.74, 0.76, 0.80, 0.92, 0.94, 1.01 (all S, 6×3H, 27-, 23-, 24-, 25-, 26-, 28-Me), 1.01-2.4 (complex CH—, CH2, 25 H,); 13C NMR (CDCl3) d 151.32, 109.67, 79.32, 55.63, 50.77, 48.63, 48.33, 43.34, 43.17, 41.16, 40.34, 39.20, 39.04, 38.38, 37.50, 35.92, 34.61, 30.18, 28.33, 27.77, 26.09, 25.47, 21.26, 19.65, 18.65, 18.35, 16.46, 16.31, 15.72, 14.89; MS (EI) 426, 411, 393, 381, 369, 315, 281, 257, 218, 207, 189, 175, 161, 147, 135, 121, 107.
  • Example 32 Betulin-28-caffeate Lup-20(29)-ene-28-ol-3-caffeate
  • [0343]
    Figure US20040097436A1-20040520-C00047
  • In a one liter round bottom one neck flask equipped with condenser a crude extract of outer birch bark (100 g) was dissolved in 500 ml of tetrahydrofuran. 10 g of aluminum triisopropoxide was added. The mixture was boiled for 1 hour, was allowed to cool to 45° C. This formed a precipitate, which was filtered and washed with tetrahydrofuran (5×40 ml) and dried on filter. Residual powder (34.2 g) was washed with 10% AcOH, dried on filter and extracted with 1% AcOH in isopropyl alcohol (5×50 ml). Combined extracts were concentrated in vacuum to 50 ml volume and diluted with water (200 ml) and filtered, and dried in vacuum at 40° C. The resulting 22.7 g of material was treated with a solution of diazomethane in diethyl ether and solvent was evaporated after no more nitrogen evolved. The remaining material was subjected for chromatography on silica gel (hexanes:ether=4:1) and 30 fractions were collected after 100 ml solvent delay and analyzed by TLC. Fractions 7, 8, 9 were combined and solvent was evaporated to give 4.78 g of lite-yellow crystals m.p. 191.1, 198.3° C., IR (KBr) 3426, 2945, 2871, 1708, 1678, 1630, 1604, 1514, 1447, 1376, 1273, 1181, 1109, 1012, 977 cm[0344] −1; 1H NMR (CDCl3), 7.602 (1H, DJ=15.9, C3′H from caffeate); 7.1 (1H, D, J=7.8, C2′-H from caffeate); 7.06 (1H, D, J=2); 6.86 (1H, DD, J=7.8, C5′H); 6.314 (1H, D, J=15.9); 4.68 (1H, S, 29-H); 4.62 (1H, M, C3H); 4.59 (1H, S, 29H); 3.82 (1H, D, J=11.5, 28H); 3.35 (1H, D, J=11.5, 28H), 1.69 (3H, S, 30-Me), 1.036, 0.991, 0.927, 0.899, 0.882 (5×3H, S, 23-, 24-, 25-, 26-, 27-Me); 1.05-2.24 (complex CH—, CH2); 13C NMR (CDCl3) 167.44, 151.29, 150.8, 149.47, 144.54, 127.82, 122.92, 116.83, 111.27, 110.06, 109.78, 81.141, 60.86, 56.28, 55.73, 50.62, 49.06, 48.11, 43.04, 41.264, 38.739, 38.39, 37.61, 37.42, 34.87, 34.30, 30.03, 29.47, 28.33, 27.35, 25.48, 24.165, 21.18, 19.39, 18.53, 17.03, 16.53, 16.31, 15.06.
  • Example 33 General Procedure for Preparation of Betulin-3,28-dioxalate-polyethylenimine Amids (Samples 49-51, 100-106):
  • In 500 ml round bottom flask to a solution of polyethylenimine (MW[0345] av 600) (a mmol) in 100 ml of dichloromethane add a solution of Betulin-3,28-dioxalylchloride (b mmol) in 300 ml of dichloromethane drop wise while stirring at 21-23° C. The reaction mixture was then stirred for 15 minutes and dichloromethane was evaporated under reduced pressure at 40° C. Residue (oily amorphous material) was dried in vacuum.
  • 49. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0346] av 600) ratio a:b=1:1;
  • 50. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0347] av 600) ratio a:b=1:3;
  • 51. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0348] av 600) ratio a:b=5:1;
  • 100. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0349] av 600) ratio a:b=1:5;
  • 101. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0350] av 600) ratio a:b=3:1;
  • 102. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0351] av 600) ratio a:b=1:10;
  • 103. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0352] av 600) ratio a:b=1:1;
  • 104. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0353] av 600) ratio a:b=1:2;
  • 105. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0354] av 600) ratio a:b=2:1;
  • 106. Betulin-3,28-dioxalylchloride:polyethylenimine (MW[0355] av 600) ratio a:b=1:4.
    Figure US20040097436A1-20040520-C00048
  • The compounds disclosed herein were tested for growth inhibition against four strains of bacteria: [0356] Escherichia coli, Staphylococcus aureus, methicillin-resistant Staphylococcus aureus, and Bacillus subtilis. These three species differ significantly in size, morphology, environment, and are evolutionarily distant. They represent three distinct genera. E. coli is a gram-negative, non-spore forming, rod-shaped, opportunistic pathogen that resides in the human digestive tract. S. aureus is a gram positive coccus, is usually found morphologically as a packet, and is an opportunistic human pathogen, often residing on or in the skin. B. subtilis is a gram positive spore-forming rod. Its native environment is the soil. The chemicals were tested for growth-inhibition of the bacteria by the Kirby-Bauer method. See, e.g., Microbiology, third edition; Lansing M. Prescott, John P. Harley, and Donald A. Klein; W m. C. Brown Publishers.
  • Materials and Methods
  • Preparation of media. Mueller-Hinton agar (Difco Lab, Michigan) was prepared according to the manufacturer's directions, and 20 ml was dispensed in each sterile petri dish. Sterile nutrient broth (Difco Lab, Michigan) was also prepared according to the manufacturer's directions. [0357]
  • Growth of organism. Bacteria were grown in liquid nutrient broth for 18 hours at 37° C. until they were turbid. [0358]
  • Preparation of plates. An aliquot of 0.5 ml of cultured bacteria was aseptically transferred to the surface of a Mueller-Hinton agar plat, and spread using a cotton-tipped swab. Plates were then allowed to dry for 5 minutes. Then a 10 mm diameter filter paper disk impregnated with the test chemical was placed with sterile forceps on the plate. The disks were impregnated with 100 μl of a solution of the test compound in DMSO or in water, at the indicated concentrations in Table 1. [0359]
  • Determination of susceptibility. The zones of inhibition were measured after 18 hours growth at 37° C. Tests were done in triplicate. [0360]
  • Determination of Minimum Inhibitory Concentration. Sterile tryptic soy broth was prepared according to the manufacturer's instructions (Difco Lab, Michigan). To each tube containing 7 ml of broth, test compounds dissolved in DMSO were added at different concentrations in triplicate. The tubes were incubated for 24 hours at 37° C. and then turbidity was measured using a colorimeter. The colorimeter was calibrated with sterile broth. The MIC was the lowest concentration that could prevent an increase in turbidity. [0361]
  • Results
  • Control disks impregnated with DMSO or 0.85% saline produced no zone of inhibition. Against [0362] E. coli, betulin-3,28-diphosphate, betulin-3,28-diglutarate, and betulin-3,28-didiglycolate were effective (Tables 1a and 1b). Each had a a minimum inhibitory concentration of 0.282 μM (data not shown).
  • The compounds effective against [0363] S. aureus were betulin-3,28-dimaleate and betulin-3,28-diphthalate (Tables 1a and 1b). Each had a minimum inhibitory concentration of 2.3 μM.
  • Against methicillin resistant [0364] S. aureus, betulin-3,28-dimaleate was effective, with an MIC of 0.282 μM.
  • No compounds tested were effective against [0365] Bacillus subtilis.
  • Betulin-3,28-dimaleate was more effective against the laboratory strain (not methicillin resistant) [0366] S. aureus than streptomycin. In the disk diffusion assay, S. aureus was inhibited by 56 ng of betulin-3,28-dimaleate applied to the disk, while inhibition by streptomycin required 10 μg.
    TABLE 1a
    Effect of Betulin, Allobetulin, and Derivatives in DMSO Solution
    Concentra- Zone of inhibition
    tion mg/ml Escherichia Staphylococcus Bacillus
    Test Compound in DMSO coli aureus subtilis
    Betulin  1 mg/ml 0 mm 0 mm 0 mm
    Allobetulin  1 mg/ml 0 mm 0 mm 0 mm
    Betulin 28-  1 mg/ml 0 mm 0 mm 0 mm
    succinate
    Betulin 3,28-  1 mg/ml 0 mm 0 mm 0 mm
    disuccinate
    Betulin 3,28- 10 mg/ml 0 mm 10.0 mm   0 mm
    diphthalate
    Betulin 3,28- 10 mg/ml 0 mm 0 mm 0 mm
    diglutarate
    Betulin 3,28- 10 mg/ml 0 mm 11.0 mm   0 mm
    dimaleate
    Betulin 3,28- 10 mg/ml 0 mm 0 mm 0 mm
    didiglycolate
    Allobetulin 3-  5 mg/ml 0 mm 0 mm 0 mm
    succinate
    Allobetulin 3-  1 mg/ml 0 mm 0 mm 0 mm
    glutarate
    Betulin 28- 10 mg/ml 0 mm 0 mm 0 mm
    maleate
    Betulin 3,28- 20 mg/ml 0 mm 0 mm 0 mm
    maleate
    Betulin 28-  1 mg/ml 0 mm 0 mm 0 mm
    phthalate
    DMSO control 0 mm 0 mm 0 mm
  • [0367]
    TABLE 1b
    Effect of Betulin, Allobetulin, and Derivatives in Water Solution
    Con-
    centration Zone of inhibition
    mg/ml Escherichia Staphylococcus Bacillus
    Test Compound in DMSO coli aureus subtilis
    Betulin 28- 125 0 mm 0 mm   0 mm
    phthalate
    Betulin 3,28- 125 0 mm 0 mm   0 mm
    diglycine
    Betulin ester 125 0 mm
    Betulin Di-(L- 125 0 mm 0 mm   0 mm
    glutamic acid γ-
    benzyl ester)
    ester
    Betulin 125 0 mm 0 mm   0 mm
    dianiline ester
    Betulin Di-(L- 125 0 mm 0 mm   0 mm
    proline) ester
    Allobetulin 125 0 mm 0 mm   0 mm
    ethanol amine
    Allobetulin 2- 125 0 mm 0 mm   0 mm
    alanine ester
    Allobetulin 125 0 mm 0 mm   0 mm
    lactone
    Lupeol 125 0 mm 0 mm   0 mm
    Lupeol-3- 125 0 mm 0 mm   0 mm
    phthalate
    Allobetulin 125 0 mm 0 mm   0 mm
    glycine
    Allobetulin 3- 125 0 mm 0 mm   0 mm
    glutarate
    Allobetulin ester 125 0 mm 0 mm   0 mm
    Allobetulin 125 0 mm 0 mm   0 mm
    ethanolamine
    carbohydrate
    Hederine 0.5 0 mm 0 mm   0 mm
    hydrate
    3-Allobetulon-1- 125 0 mm 0 mm   0 mm
    ene-2-succinate
    Betulin 3.3 0 mm 0 mm   0 mm
    arabinose
    galactan
    Allobetulon- 125 0 mm 0 mm   0 mm
    lactone-1-ene-2-
    ol
    Betulin-3,28- 125 0 mm 0 mm   0 mm
    diphenylalanine
    ester
    Lupeol-3- 125 0 mm 0 mm   0 mm
    succinate
    Allobetulin 2- 125 0 mm 0 mm   0 mm
    valine-ester
    Allobetulin 3- 125 0 mm 0 mm   0 mm
    phosphate
    Allobetulin 125 0 mm 0 mm   0 mm
    lactone
    phosphate
    Allobetulin 3- 125 0 mm 0 mm   0 mm
    phthalate
    Betulon-1,2-ene- 125 0 mm 0 mm   0 mm
    ol
    Betulin 28- 125 0 mm 0 mm   0 mm
    glutarate
    Poly (ethylene 125 0 mm 0 mm   0 mm
    glycol) bis
    (carboxymethyl)
    ester
    Allobetulin-3- 125 0 mm 0 mm   0 mm
    poly (ethylene
    glycol) bis
    (carboxymethyl)
    ether ester
    Ursolic Acid 125 0 mm 0 mm   0 mm
    Betulin 3,28- 125 11.0 mm   0 mm   0 mm
    diphosphate
    Betulin 3,28- 125 12.0 mm   0 mm   0 mm
    diglutarate
    Betulin 125 10.0 mm   0 mm   0 mm
    diglycolate
    Allobetulon 125 0 mm 0 mm   0 mm
    3β-Acetoxy- 125 0 mm 0 mm   0 mm
    19αH-19,28
    lactone oleanan
    Pencillin G 10 units 0 mm 40.0 mm   25.0 mm
    control
    Streptomycin 10 mcg  20.0 mm   15.0 mm   24.0 mm
    control
    Tetracycline 30 mcg  19.0 mm   26.0 mm   31.0 mm
    control
  • Example 34
  • Additional compounds were tested for activity against [0368] E. coli, laboratory strain S. aureus (not methicillin resistant), and B. subtilis. The compounds were tested by the disk diffusion method, as in Example 1, with application of a 10 mg/ml solution of the test compound in DMSO. The results are shown in Table 2.
  • [0369] E. coli was sensitive to betulin-3,28-diglycine, betulin-3-caffeate, and betulin-28-diglycolate. S. aureus was sensitive to betulin-3,28-di-L-valine, as well as to betulin-3,28-diphthalate. No compounds were found that inhibited B. subtilis.
    TABLE 2
    List of Compounds Tested Against Bacteria.
    Escherichia Stapylococcus Bacillus
    S. No. Compound coli aureus subtilis
    Allobetulin-3-succinate x x x
    Allobetulin lactone x x x
    Allobetulin lactone-3-acetate x x x
    Allobetulin-3-L-alanine ester x x x
    Allobetulin-3-L-valine ester x x x
    Allobetulin-3-L-proline ester x x x
    Allobetulin-3-diglycolate x x x
    Allobetulin-3-glutarate x x x
    Allobetulin-3-phthalate x x x
    Allobetulin-3-methylenamine x x x
    Allobetulin ethanolamine x x x
    hydrochloride
    Allobetulin-3-glycolate x x x
    Allobetulin-PEG-COOH x x x
    Mw = 674
    Allobetulon lactone-1-en-2- x x x
    succinate
    Allobetulon-1-ene-2-ol x x x
    Allobetulon-1-ene-2-diglycolate x x x
    Betulin-3,28-diglycine ester x x x
    Betulin-28-glycine ester x x x
    Betulin arabinose galactan x x x
    Betulin-3,28-diglycine ester o x x
    Betulin-3-maleate x x x
    Betulin-3,28-Di-L-alanine ester x x x
    Betulin-3-28-diphenylalanine x x x
    ester
    Betulin-3,28-di-L-proline ester) x x x
    Betulin-3-caffeate o x x
    Betulin-3,28-di (3′,3′-dimethyl) x x x
    glutarate
    Betulin-3,28-didiglycolate x x x
    Betulin-28-diglycolate o x x
    Betulin-3,28-diphthalate x o x
    Betulin-3,28-Di-L-phenylalanine x x x
    ester
    Betulin-3,28-Di-L-valine ester x o x
    Betulin-3,28-di-PEG-COOH x x x
    Mw = 1448
    Betulin-3,28-di-PEG-COOH x x x
    Mw = 906 crude
    Allobetulin-3,28-(dipoly x x x
    (ethylene glycol)bis (carboxy-
    methyl)
    Lupeol x x x
    Lupeol succinate x x x
    Ursolic acid x x x
  • Example 35
  • Derivatives of lupeol were tested for inhibition of bacterial growth using the Kirby-Bauer disk diffusion method and by growth in liquid culture. For the disk diffusion method, compounds were dissolved in DMSO and 100 μl was added to the 10 mm filter paper disk. The amount of compound applied to the disk varied. The amount applied for each compound was as follows: lupeol (50 μg), lupeol-3-maleate (15 μg), lupeol-3-thiodiglycolate (15 μg), lupeol-3-dimethyl succinate (60 μg), lupeol-3-phosphate (30 μg), lupenone (50 μg), lupenon-3-oxime (50 μg), lupeol-3-amine (50 μg), lupenon-1,2-ene-2-ol (50 μg). In liquid culture, the compounds were dissolved in DMSO at 1 mg/ml and then 100 μl was added to 7 ml of sterile broth, along with a 1/200 dilution of freshly grown bacterial liquid culture. The strains tested were [0370] Staphylococcus aureus, Staphylococcus epidemidis, and Enterococcus faecalis.
  • The results are shown in Tables 3 and 4. [0371]
    TABLE 3
    Antibacterial activities against Staphylococcus aureus, Staphylococcus epidemidis,
    and Enterococcus faecalis using the Kirby-Bauer disk diffusion method.
    Compounds in
    descending order
    of activity Zone of inhibition Compounds in Zone of inhibition Compounds in Zone of inhibition
    (amount applied (mm) against S. descending order (mm) against S. descending order (mm) against E.
    to the disk) epiderm. of activity aureus of activity faecalis
    Lupenon-1,2-ene-2- 2.65 Ampicillin 6.1 Ampicillin 5.75
    ol
    Ampicillin 2 Chloramphenicol 2.6 Lupeol 1.4
    Lupenone 1 Lupenone 1.25 Chloraphenicol 1.25
    Lupeol-3-maleate 0.5 Streptomycin 1.25 Lupeol-3-maleate 1.15
    Lupeol-3- 0.5 Lupeol 1 Lupeol-3- 0.75
    thiodiglycolate thiodiglycolate
    Chloramphenicol 0.5 Lupenon-1,2-ene-2- 0.85 Lupenon-1,2-ene-2- 0.6
    ol ol
    Lupeol 0 Lupeol-3-(3′,3′- 0.5 Lupenon oxime 0.6
    dimethyl)succinate
    Lupeol-3-(3′,3′- 0 Lupeol-3- 0.5 Lupenone 0.5
    dimethyl)succinate phosphate
    Lupeol-3- 0 Lupeol-3-maleate 0.4 Lupeol-3- 0.5
    phosphate phosphate
    Lupenon oxime 0 Lupenon oxime 0.4 Lupeol-3-amine 0.5
    Lupeol-3-amine 0 Lupeol-3- 0.3 Lupeol-3-(3′,3′- 0
    thiodiglycolate dimethyl)succinate
    Gentamicin 0 Lupeol-3-amine 0.3 Gentamicin 0
    Streptomycin 0 Gentamicin 0.1 Streptomycin 0
  • [0372]
    TABLE 4
    Antibacterial activity against Staphylococcus aureus, Staphylococcus epidermis,
    and Enterococcus faecilis using optical density measurements. Optical density
    at 600 nm of bacteria in liquid culture was measured after growth for 24 hours in
    the presence of the test compound at 14 μg per ml.
    Compounds in Compounds in Compounds in
    descending order of Optical Density of descending order of Optical Density of descending order of Optical Density of
    activity S. epiderm. activity S. aureus activity E. faecalis
    Lupenon-1,2-ene-2- 0.006 Lupenon-1,2-ene-2- 0.04 Lupenon-1,2-ene-2- 0.01
    ol ol ol
    Lupenone 0.03 Lupenone 0.04 Lupeol-3-maleate 0.03
    Lupeol-3- 0.035 Lupeol 0.06 Lupeol 0.03
    thiodiglycolate
    Lupeol 0.04 Lupeol-3-maleate 0.06 Lupeol-3- 0.04
    phosphate
    Lupeol-3-maleate 0.04 Lupeol-3- 0.06 Lupenone 0.04
    thiodiglycolate
    Lupeol-3-(3′3′- 0.06 Lupeol-3-(3′,3′- 0.06 Lupeol-3-amine 0.04
    dimethyl)succinate dimethyl)succinate
    Lupeol-3- 0.06 Lupeol-3- 0.06 Lupeol-3- 0.04
    phosphate phosphate thiodiglycolate
    Lupenon oxime 0.06 Lupenon oxime 0.06 Lupenon oxime 0.45
    Lupeol-3-amine 0.06 Lupeol-3-amine 0.06 Lupeol-(3′,3′- 0.07
    dimethyl)succinate
    None 0.07 None 0.08 None 0.85
  • The results with the disk diffusion method and by liquid growth were consistent with each other. Lupenon-1,2-ene-2-ol was the most active compound against almost all the bacteria, especially as measured in liquid growth. Lupenone also had excellent activity. Against [0373] S. epidermidis, lepeol-3-thiodiglycolate lupeol-3-maleate, and lupeol were active. Against S. aureus, all the tested compounds showed some activity. Against E. faecalis, all the compounds except lupeol-3-(3′,3′-dimethyl)succinate showed activity.
  • The compounds shown to be active against at least one strain of bacteria in the assays above are the following: betulin-3-caffeate; betulin-3,28-diglutarate; betulin-28-diglycolate; betulin-3,28-diglycine; betulin-3,28-didiglycolate; betulin-3,28-diphthalate; betulin-3,28-diphosphate; betulin-3,28-disuccinate; betulin-3,28-di-L-valine; lupeol; lupeol-3-amine; lupeol-3-(3′,3′-dimethyl)succinate; lupeol-3-maleate; lupeol-3-phosphate; lupeol-3-thiodiglycolate; lupenone; lupenon-1,2-ene-2-ol; lupenon-3-oxime. [0374]
  • All publications, patents, and patent documents are incorporated by reference herein, as though individually incorporated by reference. The invention has been described with reference to various specific and preferred embodiments and techniques. However, it should be understood that many variations and modifications may be made while remaining within the spirit and scope of the invention. [0375]

Claims (48)

What is claimed is:
1. A therapeutic method of treating a mammal afflicted with a bacterial infection comprising administering to the mammal an effective anti-bacterial amount of a triterpene of formula (I):
Figure US20040097436A1-20040520-C00049
wherein
R1 is hydrogen or hydroxy;
R2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl;
R3 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside;
R4 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, a glycoside, or amino; or R4 and R5 together are oxo or (═NOH); and
R5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo or (═NOH);
wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; —OP(═O)(OH)2; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
each of the bonds represented by—is independently absent or is present;
wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol);
wherein any alkyl is optionally partially unsaturated;
wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 wherein R4 is not amino; R4 and R5 are not together (═NOH); and alkyl is not substituted with —OP(═O)(OH)2.
3. The method of claim 1 wherein the bond between carbons 1 and 2 is a single bond.
4. The method of claim 1 wherein the bond between carbons 1 and 2 is a double bond.
5. The method of claim 1 wherein R1 is hydrogen.
6. The method of claim 1 wherein R1 is hydroxy.
7. The method of claim 1 wherein R2 is a direct bond.
8. The method of claim 7 wherein R3 is (C1-C6)alkyl; wherein
any alkyl can optionally be substituted with one or more oxo, carboxy, amino, (C6-C10)aryl, or —OP(═O)(OH)2,;
any alkyl is optionally interrupted on carbon with one or more oxy or thio;
any alkyl is optionally partially unsaturated; and
any aryl can optionally be substituted with one or more hydroxy or carboxy.
9. The method of claim 8 wherein R3 is 3-carboxypropenoyloxymethyl, aminoacetoxymethyl, (carboxymethoxy)acetoxymethyl, 4-carboxybutanoyloxymethyl, 2-carboxybenzoyloxymethyl, butanoyloxymethyl, or
—CH2OC(═O)OP(═O)(OH)2.
10. The method of claim I wherein R4 is (C1-C6)alkyl; wherein
any alkyl can optionally be substituted with one or more oxo, carboxy, amino, (C6-C10)aryl, or —OP(═O)(OH)2, (C6-C10)aryl;
any alkyl is optionally interrupted on carbon with one or more oxy or thio;
any alkyl is optionally partially unsaturated; and
any aryl can optionally be substituted with one or more hydroxy or carboxy.
11. The method of claim 1 wherein R4 is 2-carboxybenzoyl, 2-amino-3-methylbutanoyl, 3-carboxypropenoyl, aminoacetyl, 4-carboxybutanoyl, (carboxymethoxy)acetyl, 3-(3,4-dihydroxyphenyl)propenoyl, carboxymethylenethioacetyl, 3-carboxy-3-methylbutanoyl, amino, —P(═O)(OH)2, oxo, or (═NOH).
12. The method of claim 1 wherein R5 is oxy or a direct bond.
13. The method of claim 1 wherein
R1 is hydrogen or hydroxy;
R2 is a direct bond;
R3 is (C1-C5)alkoxymethyl or hydroxymethyl;
R4 is hydrogen, phosphono, sulfo, or (C1-C6)alkyl, and R5 is oxy; or
R4 is amino and R5 is a direct bond; or
R4 and R5 together are oxo or (═NOH);
wherein any alkyl, or alkyl segment of an R group, is optionally interrupted on carbon with one or more oxy, thio, or imido;
wherein any alkyl, or alkyl segment of an R group, can optionally be substituted with one or more oxo, carboxy, amino, —OP(═O)(OH)2, or phenyl;
wherein phenyl can optionally be substituted with one or more hydroxy or carboxy.
14. The method of claim 1 wherein
R1 is hydrogen or hydroxy;
R2 is a direct bond;
R3 is 3-carboxypropenoyloxymethyl, aminoacetoxymethyl, (carboxmethox)acetoxymethyl, 4-carboxybutanoyloxymethyl, 2-carboxybenzoyloxymethyl, butanoyloxymethyl, or
—CH2OC(═O)OP(═O)(OH)2;
R4 is 2-carboxybenzoyl, 2-amino-3-methylbutanoyl, 3-carboxypropenoyl, aminoacetyl, 4-carboxybutanoyl, (carboxymethoxy)acetyl, 3-(3,4-dihydroxyphenyl)propenoyl, carboxymethylenethioacetyl, 3-carboxy-3-methylbutanoyl, amino, —P(═O)(OH)2, oxo, or (═NOH); and
R5 is oxy or a direct bond.
15. The method of claim 1 wherein the triterpene is betulin; betulin-3,28-diglycine; betulin-28-glycerol oxalate; betulin-28-glycine; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28didiglycolate; betulin-3,28-diglycine; betulin-3-maleate; betulin-3,28-di-(L-glutamic acid γ-benzylester) ester; betulin-3,28-di-L-alanine; betulin-3,28-di-L-proline; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-diphenylalanine; betulin-3-28-dioxalate-polyethylene amine; betulin-3,38-diphosphate; betulin-3-caffeate; betulin-3,28-(3′,3′-dimethyl) glutarate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-di(3′,3′-dimethyl)glutarate; betulin-3,28-didiglycolate; betulin-3,28-di(thiodiglycolate); betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-phenylalanine; betulin-3,28—di-L-valine; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=1448); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 crude); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; betulin-3,28-(dipoly(ethylene glycol)bis (carboxymethylester); allobetulin-3,28-(dipoly(ethylene glycol)bis (carboxymethyl allobetulin ester); hederin hydrate; lupeol; lupeol-3-glutarate; lupeol-3-succinate; lupeol-3-thiodiglycolate; lupeol-3-phthalate; oleanolic acid; ursolic acid; or uvaol.
16. The method of claim 1 wherein the triterpene is betulin; betulin-28-glycerol oxalate; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28-didiglycolate; betulin-3,28-diglycine; betulin-3,28-di-(L-glutamic acid γ-benzylester) ester; betulin3,28-di-L-proline ester; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-dioxalate-polyethylene amine; betulin-3,28-diphosphate; betulin-3-caffeate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-dithiodiglycolate; betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-phenylalanine; betulin-di-L-valine; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; betulin-3,28-(dipoly(ethylene glycol)bis (carboxymethylester); hederin hydrate; lupeol-3-glutarate; lupeol-3-succinate; lupeol-3-thiodiglycolate; lupeol-3-phthalate; oleanolic acid; uvaol.
17. The method of claim 1 wherein the triterpene is betulin-3-caffeate; betulin-28-diglycolate; betulin-3,28-diglutarate; betulin-3,28-diglycine; betulin-3,28-didiglycolate; betulin-3,28-dimaleate; betulin-3,28-diphosphate; betulin-3,28-diphthalate; betulin-3,28-di-L-valine; lupeol; lupeol-3-amine; lupeol-3-(3′,3′-dimethyl)succinate; lupeol-3-maleate; lupeol-3-phosphate; lupeol-3-thiodiglycolate; lupenone; lupenon-1,2-ene-2-ol; lupenon-3-oxime.
18. The method of claim 1 wherein the bacterial infection is caused by Escherichia coli, Staphylococcus sp., Enterococcus faecalis, or a combination thereof.
19. The method of claim 18 wherein the bacterial infection is caused by Staphylococcus aureus.
20. A therapeutic method of treating a mammal afflicted with a bacterial infection comprising administering to the mammal an effective anti-bacterial amount of a triterpene of formula (II):
Figure US20040097436A1-20040520-C00050
wherein
one of R1 and R2 is —O—Y and the other is hydrogen or (C1-C6)alkyl optionally substituted by hydroxy, (C1-C6)alkoxy, halo, halo(C1-C6)alkoxy or NRjRk wherein Rj and Rk are independently H, (C1-C6)alkyl or (C1-C6)alkonyl; or R1 and R2 together are oxo (═O);
R3 is hydrogen, halo, carboxy, mercapto, (C1-C6)alkyl, (C3-C8)cycloalkyl, or —O—Y;
R4 and R5 are each independently hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl;
R6 is hydrogen or is absent when the adjacent—is a bond;
R7 is hydrogen or (C1-C6)alkyl;
R8 is hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl and R11 is hydrogen, (C1-C6)alkyl, carboxy, or hydroxy(C1-C6)alkyl; or R8 and R11 together are —O—C(═X)—;
R9 and R10, are each independently hydrogen or (C1-C6)alkyl;
each of the bonds represented by—is independently absent or is present;
X is two hydrogens, oxo (═O) or thioxo (═S);
each Y is independently H, aryl, P(O)(Cl)2, (C3-C8)cycloalkyl, adamantyl, —SO2Ra O═P(Rb)2, O═P(Rc)2OP(O)(Rd)—, Si(Re)3, tetrahydropyran-2-yl, an amino acid, a peptide, a glycoside, or a 1 to 10 membered branched or unbranched carbon chain optionally comprising 1, 2, or 3 heteroatoms selected from non-peroxide oxy, thio, and —N(Rf)—; wherein said chain may optionally be substituted on carbon with 1, 2, 3, or 4 oxo (═O), hydroxy, carboxy, halo, mercapto, nitro, —N(Rg)(Rh), (C3-C8)cycloalkyl, (C3-C8)cycloalkyloxy, aryl, aryloxy, adamantyl, adamantyloxy, hydroxyamino, trifluoroacetylamino, a glycoside, an amino acid, or a peptide; and wherein said chain may optionally be saturated or unsaturated (e.g. containing one, two, three or more, double or triple bonds);
Ra is (C1-C6)alkyl or aryl;
Rb, Rc, and Rd are each independently hydroxy, (C1-C6)alkoxy, hydroxy(C2-C6)alkoxy, adamantyloxy, adamantyl(C1-C6)alkoxy, norbornyloxy, 1,1-di(hydroxymethyl)-2-hydroxyethoxy, carboxy(C1-C6)alkoxy, 2,3-epoxypropyloxy, benzyloxy, (C3-C8)cycloalkyloxy, NRxRy, or aryloxy;
Re is H, aryl or (C1-C6)alkyl;
Rf is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl or benzyl;
Rg and Rh are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, adamantyl, adamantyl(C1-C6)alkyl, amino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkanoyl, aryl and benzyl; or Rb and Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, or morpholino radical; and
Rx and Ry are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, aryl or benzyl;
wherein each aryl of Y, Ra—Rd, Rg—Rh, Rx, and Ry may optionally be substituted by 1, 2, or 3 aminosulfonyl, carboxy, NRiRj, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, halo, nitro, cyano, mercapto, carboxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, trifluoromethoxy, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, or (C1-C6)alkanoyloxy; wherein Ri and Rj are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl, or benzyl;
wherein any alkyl can optionally be substituted with one or more polyethyleneimine or poly(ethylene glycol); and wherein any alkyl can optionally be interrupted with one or more polyethyleneimine or poly(ethylene glycol);
or a pharmaceutically acceptable salt thereof.
21. The method of claim 20 wherein the triterpenoid is 3-β-acetoxy-19αH-19,28 lactone oleanan; allobetulin; allobetulin-3-succinate; allobetulin-3-glycine ester; allobetulin lactone; allobetulin lactone-3-acetate; allobetulin lactone-3-phosphate; allobetulin-3-L-alanine; allobetulin-3-L-valine; allobetulin-3-L-proline; allobetulin-3-succinate; allobetulin-3-diglycolate; allobetulin-3-glutarate; allobetulin-3-phthalate; allobetulin-3-methylenamine; allobetulin-3-ethanolamine; allobetulin-3-ethanolamine hydrochloride; allobetulin-3-glycolate; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulin-3-(polyethylene glycol)-COOH (Mw=674); allobetulon; allobetulon lactone-1-ene-2-ol; allobetulon lactone-1-en-2-succinate; allobetulon-1-ene-2-ol; allobetulon-1-ene-2-diglycolate; 3-allobetulon-1-ene-2-succinate; or 3-allobetulon-1-ene-2-diglycolate.
22. The method of claim 20 wherein the triterpenoid is 3-β-acetoxy-19αH-19,28 lactone oleanan; allobetulin; allobetulin-3-glycine ester; allobetulin lactone-3-phosphate; allobetulin-3-succinate; allobetulin-3-ethanolamine; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulon; allobetulon lactone-1-ene-2-ol; 3-allobetulon-1-ene-2-succinate; or ursolic acid.
23. A method of inhibiting or killing a bacterium, comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (I):
Figure US20040097436A1-20040520-C00051
wherein
R1 is hydrogen or hydroxy;
R2 is a direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl;
R3 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, or a glycoside;
R4 is hydrogen, hydroxy, (C1-C6)alkyl, O═P(OH)2, O═P(OH)2OP(O)(OH)—, (C1-C5)alkanoyl, Si(R)3 wherein each R is H, phenyl or (C1-C6)alkyl, C(O)N(R)2, benzyl, benzoyl, tetrahydropyran-2-yl, 1-[(C1-C4)alkoxy](C1-C4)alkyl, a glycoside, or amino; or R4 and R5 together are oxo or (═NOH); and
R5 is direct bond, carbonyl, oxy, thio, carbonyl oxy, oxy carbonyl, (C6-C10)aryl, or (C1-C6)alkyl; or R4 and R5 together are oxo or (═NOH);
wherein any alkyl can optionally be substituted with one or more halo, hydroxy, (C6-C10)aryl, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; —OP(═O)(OH)2; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
each of the bonds represented by - - - is independently absent or is present;
wherein any alkyl is optionally interrupted on carbon with one or more oxy, thio, sulfinyl, sulfonyl, polyethyleneimine, or poly(ethylene glycol);
wherein any alkyl is optionally partially unsaturated;
wherein any aryl can optionally be substituted with one or more halo, hydroxy, nitro, cyano, (C1-C6)alkoxy, trifluoromethyl, polyethyleneimine, poly(ethylene glycol), oxo, NR7R8, wherein R7 and R8 are each independently hydrogen, (C1-C6)alkyl or polyethyleneimine; or C(═O)OR9, wherein R9 is hydrogen, (C1-C6)alkyl, or polyethyleneimine;
or a pharmaceutically acceptable salt thereof.
24. The method of claim 23 wherein R4 is not amino; R4 and R5 are not together (═NOH); and alkyl is not substituted with —OP(═O)(OH)2.
25. The method of claim 23 wherein the bond between carbons 1 and 2 is a single bond.
26. The method of claim 23 wherein the bond between carbons 1 and 2 is a double bond.
27. The method of claim 23 wherein R1 is hydrogen.
28. The method of claim 23 wherein R1 is hydroxy.
29. The method of claim 23 wherein R2 is a direct bond.
30. The method of claim 29 wherein R3 is (C1-C6)alkyl,
wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino, (C6-C10)aryl, or —OP(═O)(OH)2,;
wherein any alkyl is optionally interrupted on carbon with one or more oxy or thio;
wherein any alkyl is optionally partially unsaturated;
wherein any aryl can optionally be substituted with one or more hydroxy or carboxy.
31. The method of claim 30 wherein R3 is aminoacetoxymethyl, (carboxymethoxy)acetoxymethyl, 4-carboxybutanoyloxymethyl, 2-carboxybenzoyloxymethyl, 3-carboxypropanoyloxymethyl, butanoyloxymethyl, or
—CH2OC(═O)OP(═O)(OH)2.
32. The method of claim 23 wherein R4 is (C1-C6)alkyl,
wherein any alkyl can optionally be substituted with one or more oxo, carboxy, amino, (C6-C10)aryl, or —OP(═O)(OH)2,;
wherein any alkyl is optionally interrupted on carbon with one or more oxy or thio;
wherein any alkyl is optionally partially unsaturated;
wherein any aryl can optionally be substituted with one or more hydroxy or carboxy.
33. The method of claim 23 wherein R4 is 2-carboxybenzoyl, 2-amino-3-methylbutanoyl, 3-carboxypropenoyl, aminoacetyl, 4-carboxybutanoyl, (carboxymethoxy)acetyl, 3-(3,4-dihydroxyphenyl)propenoyl, carboxymethylenethioacetyl, 3-carboxy-3-methylbutanoyl, amino, —P(═O)(OH)2, oxo, or (═NOH).
34. The method of claim 23 wherein R5 is oxy or a direct bond.
35. The method of claim 23 wherein
R1 is hydrogen or hydroxy;
R2 is a direct bond;
R3 is (C1-C5)alkoxymethyl or hydroxymethyl;
R4 is hydrogen, phosphono, sulfo, or (C1-C6)alkyl, and R5 is oxy; or
R4 is amino and R5 is a direct bond; or
R4 and R5 together are oxo or (═NOH);
wherein any alkyl, or alkyl segment of an R group, is optionally interrupted on carbon with one or more oxy, thio, or imido;
wherein any alkyl, or alkyl segment of an R group, can optionally be substituted with one or more oxo, carboxy, amino, —OP(═O)(OH)2, or phenyl;
wherein phenyl can optionally be substituted with one or more hydroxy or carboxy.
36. The method of claim 23 wherein
R1 is hydrogen or hydroxy;
R2 is a direct bond;
R3 is aminoacetoxymethyl, (carboxmethox)acetoxymethyl, 4-carboxybutanoyloxymethyl, 2-carboxybenzoyloxymethyl, 3-carboxypropanoyloxymethyl, butanoyloxymethyl, or
—CH2OC(═O)OP(═O)(OH)2;
R4 is 2-carboxybenzoyl, 2-amino-3-methylbutanoyl, 3-carboxypropenoyl, aminoacetyl, 4-carboxybutanoyl, (carboxymethoxy)acetyl, 3-(3,4-dihydroxyphenyl)propenoyl, carboxymethylenethioacetyl, 3-carboxy-3-methylbutanoyl, amino, —P(═O)(OH)2, oxo, or (═NOH); and
R5 is oxy or a direct bond.
37. The method of claim 23 wherein the triterpene is betulin; betulin-3,28-diglycine; betulin-28-glycerol oxalate; betulin-28-glycine; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28didiglycolate; betulin-3,28-diglycine; betulin-3-maleate; betulin-3,28-di-(L-glutamic acid γ-benzylester) ester; betulin-3,28-di-L-alanine; betulin-3,28-di-L-proline; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-diphenylalanine; betulin-3-28-dioxalate-polyethylene amine; betulin-3,38-diphosphate; betulin-3-caffeate; betulin-3,28-(3′,3′-dimethyl) glutarate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-di(3′,3′-dimethyl)glutarate; betulin-3,28-didiglycolate; betulin-3,28-di(thiodiglycolate); betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-phenylalanine; betulin-3,28-di-L-valine; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=1448); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 crude); betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; 3,28 (dipoly(ethylene glycol)bis (carboxymethylester); 3,28 (dipoly(ethylene glycol)bis (carboxymethyl allobetulin ester); hederin hydrate; lupeol; lupeol-3-glutarate; lupeol-3-succinate; lupeol-3-thiodiglycolate; lupeol-3-phthalate; lupeol-3-succinate; oleanolic acid; ursolic acid; or uvaol.
38. The method of claim 23 wherein the triterpene is betulin; betulin-28-glycerol oxalate; betulin-28-oxalate; betulin arabinose galactan; betulin-3,28-didiglycolate; betulin-3,28-diglycine; betulin-3,28-di-(L-Glutamic acid r-benzylester) ester; betulin3,28-di-L-proline ester; betulin-3,28-dioxalate; betulin-1-ene-2-ol; betulin-3,28-dioxalate-polyethylene amine; betulin-3,28-diphosphate; betulin-3-caffeate; betulin-28-diglycolate; betulin-28-glutarate; betulin-28-maleate; betulin-28-phthalate; betulin-3,28-dithiodiglycolate; betulin-3,28-diglutarate; betulin-3,28-dimaleate; betulin-3,28-diglycolate; betulin-3,28-diphthalate; betulin-3,28-di-L-phenylalanine; betulin-di-L-valine; betulin-28-succinate; betulin-3,28-disuccinate; betulin-3,28-di-(polyethylene glycol)-COOH (Mw=906 pure); betulinic acid; betulon-1-ene-2-ol; betulin-3,28-(dipoly(ethylene glycol)bis (carboxymethylester); hederin hydrate; lupeol-3-glutarate; lupeol-3-succinate; lupeol-3-thiodiglycolate; lupeool-3-phthalate; oleanolic acid; uvaol.
39. The method of claim 23 wherein the triterpene is betulin-3-caffeate; betulin-28-diglycolate; betulin-3,28-diglutarate; betulin-3,28-diglycine; betulin-3,28-didiglycolate; betulin-3,28-dimaleate; betulin-3,28-diphosphate; betulin-3,28-diphthalate; betulin-3,28-di-L-valine; lupeol; lupeol-3-amine; lupeol-3-(3′,3′-dimethyl)succinate; lupeol-3-maleate; lupeol-3-phosphate; lupeol-3-thiodiglycolate; lupenone; lupenon-1,2-ene-2-ol; lupenon-3-oxime.
40. The method of claim 23 wherein the bacterium is Escherichia coli, Staphylococcus sp., Enterococcus faecalis, or a combination thereof.
41. The method of claim 40 wherein the bacterium is Staphyloccoccus aureus.
42. The method of claim 23 wherein the contacting is in vitro.
43. The method of claim 23 wherein the contacting is in vivo.
44. A method of inhibiting or killing a bacterium, comprising contacting the bacterium with an effective antibacterial amount of a triterpene of formula (II):
Figure US20040097436A1-20040520-C00052
wherein
one of R1 and R2 is —O—Y and the other is hydrogen or (C1-C6)alkyl optionally substituted by hydroxy, (C1-C6)alkoxy, halo, halo(C1-C6)alkoxy or NRjRk wherein Rj and Rk are independently H, (C1-C6)alkyl or (C1-C6)alkonyl; or R1 and R2 together are oxo (═O);
R3 is hydrogen, halo, carboxy, mercapto, (C1-C6)alkyl, (C3-C8)cycloalkyl, or —O—Y;
R4 and R5 are each independently hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl;
R6 is hydrogen or is absent when the adjacent—is a bond;
R7 is hydrogen or (C1-C6)alkyl;
R8 is hydrogen, (C1-C6)alkyl, or hydroxy(C1-C6)alkyl and R11 is hydrogen, (C1-C6)alkyl, carboxy, or hydroxy(C1-C6)alkyl; or R8 and R11 together are —O—C(═X)—;
R9 and R10, are each independently hydrogen or (C1-C6)alkyl;
each of the bonds represented by—is independently absent or is present;
X is two hydrogens, oxo (═O) or thioxo (═S);
each Y is independently H, aryl, P(O)(Cl)2, (C3-C8)cycloalkyl, adamantyl, —SO2Ra O═P(Rb)2, O═P(Rc)2OP(O)(Rd)—, Si(Re)3, tetrahydropyran-2-yl, an amino acid, a peptide, a glycoside, or a 1 to 10 membered branched or unbranched carbon chain optionally comprising 1, 2, or 3 heteroatoms selected from non-peroxide oxy, thio, and —N(Rf)—; wherein said chain may optionally be substituted on carbon with 1, 2, 3, or 4 oxo (═O), hydroxy, carboxy, halo, mercapto, nitro, —N(Rg)(Rh), (C3-C8)cycloalkyl, (C3-C8)cycloalkyloxy, aryl, aryloxy, adamantyl, adamantyloxy, hydroxyamino, trifluoroacetylamino, a glycoside, an amino acid, or a peptide; and wherein said chain may optionally be saturated or unsaturated (e.g. containing one, two, three or more, double or triple bonds);
Ra is (C1-C6)alkyl or aryl;
Rb, Rc, and Rd are each independently hydroxy, (C1-C6)alkoxy, hydroxy(C2-C6)alkoxy, adamantyloxy, adamantyl(C1-C6)alkoxy, norbornyloxy, 1,1-di(hydroxymethyl)-2-hydroxyethoxy, carboxy(C1-C6)alkoxy, 2,3-epoxypropyloxy, benzyloxy, (C3-C8)cycloalkyloxy, NRxRy, or aryloxy;
Re is H, aryl or (C1-C6)alkyl;
Rf is hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl or benzyl;
Rg and Rh are each independently selected from the group consisting of hydrogen, (C1-C6)alkyl, hydroxy(C1-C6)alkyl, adamantyl, adamantyl(C1-C6)alkyl, amino(C1-C6)alkyl, aminosulfonyl, (C1-C6)alkanoyl, aryl and benzyl; or Rb and Rc together with the nitrogen to which they are attached form a pyrrolidino, piperidino, or morpholino radical; and
Rx and Ry are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, aryl or benzyl;
wherein each aryl of Y, Ra—Rd, Rg—Rh, Rx, and Ry may optionally be substituted by 1, 2, or 3 aminosulfonyl, carboxy, NRiRj, (C1-C6)alkyl, (C1-C6)alkoxy, hydroxy, halo, nitro, cyano, mercapto, carboxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, trifluoromethoxy, (C1-C6)alkanoyl, (C1-C6)alkoxycarbonyl, (C1-C6)alkylthio, or (C1-C6)alkanoyloxy; wherein Ri and Rj are each independently hydrogen, (C1-C6)alkyl, (C1-C6)alkanoyl, phenyl, or benzyl;
wherein any alkyl can optionally be substituted with one or more polyethyleneimine or poly(ethylene glycol); and wherein any alkyl can optionally be interrupted with one or more polyethyleneimine or poly(ethylene glycol);
or a pharmaceutically acceptable salt thereof.
45. The method of claim 44 wherein the triterpenoid is 3-β-acetoxy-19αH-19,28 lactone oleanan; allobetulin; allobetulin-3-succinate; allobetulin-3-glycine ester; allobetulin lactone; allobetulin lactone-3-acetate; allobetulin lactone-3-phosphate; allobetulin-3-L-alanine; allobetulin-3-L-valine; allobetulin-3-L-proline; allobetulin-3-succinate; allobetulin-3-diglycolate; allobetulin-3-glutarate; allobetulin-3-phthalate; allobetulin-3-methylenamine; allobetulin-3-ethanolamine; allobetulin-3-ethanolamine hydrochloride; allobetulin-3-glycolate; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulin-3-(polyethylene glycol)-COOH (Mw=674); allobetulon; allobetulon lactone-1-ene-2-ol; allobetulon lactone-1-en-2-succinate; allobetulon-1-ene-2-ol; allobetulon-1-ene-2-diglycolate; 3-allobetulon-1-ene-2-succinate; or 3-allobetulon-1-ene-2-diglycolate.
46. The method of claim 44 wherein the triterpenoid is 3-β-acetoxy-19αH-19,28 lactone oleanan; allobetulin; allobetulin-3-glycine ester; allobetulin lactone-3-phosphate; allobetulin-3-succinate; allobetulin-3-ethanolamine; allobetulin-3-glutarate; allobetulin-28-glutarate; allobetulin-3-methylamine HCl; allobetulin-3-phosphate; allobetulon; allobetulon lactone-1-ene-2-ol; 3-allobetulon-1-ene-2-succinate; or ursolic acid.
47. The method of claim 44 wherein the contacting is in vitro.
48. The method of claim 44 wherein the contacting is in vivo.
US10/705,022 2000-09-29 2003-11-11 Triterpenes having antibacterial activity Abandoned US20040097436A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US23651000P true 2000-09-29 2000-09-29
US09/969,556 US6689767B2 (en) 2000-09-29 2001-10-01 Triterpenes having antibacterial activity
US10/705,022 US20040097436A1 (en) 2000-09-29 2003-11-11 Triterpenes having antibacterial activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/705,022 US20040097436A1 (en) 2000-09-29 2003-11-11 Triterpenes having antibacterial activity

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/969,556 Division US6689767B2 (en) 2000-09-29 2001-10-01 Triterpenes having antibacterial activity

Publications (1)

Publication Number Publication Date
US20040097436A1 true US20040097436A1 (en) 2004-05-20

Family

ID=22889812

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/969,556 Active 2022-02-21 US6689767B2 (en) 2000-09-29 2001-10-01 Triterpenes having antibacterial activity
US10/705,022 Abandoned US20040097436A1 (en) 2000-09-29 2003-11-11 Triterpenes having antibacterial activity

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/969,556 Active 2022-02-21 US6689767B2 (en) 2000-09-29 2001-10-01 Triterpenes having antibacterial activity

Country Status (3)

Country Link
US (2) US6689767B2 (en)
AU (1) AU9495901A (en)
WO (1) WO2002026762A1 (en)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048892A1 (en) * 2008-04-18 2010-02-25 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US20100048887A1 (en) * 2008-04-18 2010-02-25 Eric Anderson Compounds including an anti-inflammatory pharmacore and methods of use
US8124656B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8394967B2 (en) 2008-04-18 2013-03-12 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US8513436B2 (en) 2010-12-17 2013-08-20 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US8993640B2 (en) 2012-04-27 2015-03-31 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
CN104877015A (en) * 2014-02-28 2015-09-02 中国人民解放军军事医学科学院毒物药物研究所 Triterpene-polypeptide conjugate, drug composition and uses thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9290536B2 (en) 2011-03-11 2016-03-22 Reata Pharmaceuticals, Inc. C4 monomethyl triterpenoid derivatives and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9593074B2 (en) 2012-09-10 2017-03-14 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9757359B2 (en) 2008-01-11 2017-09-12 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689767B2 (en) * 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US8084046B2 (en) * 2001-10-02 2011-12-27 Kimberly-Clark Worldwide, Inc. Inhibition of exoprotein production in absorbent articles using isoprenoids
US6534548B1 (en) 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
US7365221B2 (en) * 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2005021007A1 (en) * 2003-08-28 2005-03-10 Obschestvo S Ogranichennoi Otvetstvennostju 'berezovy Mir' Prevention and treatment of viral hepatitis c
US20050266105A1 (en) * 2004-02-19 2005-12-01 Ashiagbor Kwame T Compositions comprising natural agents for the treatment of HIV-associated opportunistic infections and complications and methods for preparing and using compositions comprising natural agents
DE102004030044A1 (en) * 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger oleogel, triterpenhaltiges oleogel and method for producing a triterpenhaltigen oleogel
US7893263B2 (en) * 2004-07-08 2011-02-22 Laila Nutraceuticals Structural analogs of corosolic acid having anti-diabetic and anti-inflammatory properties
US20060154903A1 (en) * 2004-09-10 2006-07-13 Cornell Research Foundation, Inc. Betulinol derivatives as anti-cancer agents
TW200628161A (en) * 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US20090131714A1 (en) * 2005-06-08 2009-05-21 Krasutsky Pavel A Synthesis of betulonic and betulinic aldehydes
CA2611435C (en) * 2005-06-10 2013-01-08 Pola Chemical Industries Inc. Novel triterpenic acid derivative and preparation for external application for skin comprising the same
KR20080099230A (en) * 2005-10-24 2008-11-12 스타발 파마, 리미티드 Method for treating/controlling/killing fungi and bacteria
US20080220103A1 (en) * 2005-10-24 2008-09-11 Jay Birnbaum Method for treating/controlling/killing fungi and bacteria on living animals
FI121468B (en) * 2006-06-07 2010-11-30 Valtion Teknillinen Betuliiniperäiset compounds as antimicrobial agents
FI20065389A (en) * 2006-06-07 2007-12-31 Valtion Teknillinen Betuliiniperäiset compounds as inhibitors of plant-eating pests
US20080039428A1 (en) * 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
GB2462235B8 (en) 2007-05-11 2013-03-27 Biotechnology Res Corp Ltd Receptor modulators exhibiting neuroprotective andmemory enhancing activities
WO2009090063A1 (en) * 2008-01-16 2009-07-23 Jado Technologies Gmbh Steroid sapogenin, androstane and triterpenoid sapogenin derivatives for the treatment and prevention of infectious diseases
RU2502839C2 (en) * 2008-08-15 2013-12-27 Геркулес Инкорпорейтед Cellulose additives for reducing resin content in kraft pulp
PT2437606T (en) * 2009-05-18 2016-09-22 Telomerase Activation Sciences Inc Compositions and methods for increasing telomerase activity
CN102603858B (en) * 2012-03-02 2014-07-02 东北林业大学 Azacycle-containing derivative of betulinol, preparation method thereof, and purpose thereof
CN103768078B (en) 2012-10-22 2019-02-05 北京大学 Tetraterpene derivatives and its anti influenza purposes
RU2660649C1 (en) * 2017-10-18 2018-07-09 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Method for the preparation of salts of betulin 3,28-diphosphate

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
US4606911A (en) * 1984-07-27 1986-08-19 Rohto Pharmaceutical Co. Ltd. Pharmaceutical composition for the prevention of dental caries
US4608392A (en) * 1983-08-30 1986-08-26 Societe Anonyme Dite: L'oreal Method for producing a non greasy protective and emollient film on the skin
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5190979A (en) * 1988-06-24 1993-03-02 Stephen Herman Ozonides of terpenes and their medical uses
US5750578A (en) * 1997-02-11 1998-05-12 Regents Of The University Of Minnesota Use of betulin and analogs thereof to treat herpesvirus infection
US5883074A (en) * 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
US6303589B1 (en) * 1998-12-08 2001-10-16 Micro Flo Company Pentacyclic triterpenes
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6689767B2 (en) * 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303120B1 (en) 1994-03-15 2001-10-16 Memorial Sloan-Kettering Institute For Cancer Research Synthesis of glycoconjugates of the lewis y epitope and uses thereof
US5708163A (en) 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
WO1998032443A1 (en) * 1997-01-24 1998-07-30 Marigen S.A. Ultramicro-emulsions of spontaneously dispersible concentrates containing antitumorally, antivirally and antiparasitically active esters of pentacyclic triterpenes
US6369109B1 (en) * 1998-10-28 2002-04-09 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumor

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
US4608392A (en) * 1983-08-30 1986-08-26 Societe Anonyme Dite: L'oreal Method for producing a non greasy protective and emollient film on the skin
US4606911A (en) * 1984-07-27 1986-08-19 Rohto Pharmaceutical Co. Ltd. Pharmaceutical composition for the prevention of dental caries
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5190979A (en) * 1988-06-24 1993-03-02 Stephen Herman Ozonides of terpenes and their medical uses
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5883074A (en) * 1995-02-08 1999-03-16 Microcide Pharmaceuticals, Inc. Potentiators of antibacterial agents
US5750578A (en) * 1997-02-11 1998-05-12 Regents Of The University Of Minnesota Use of betulin and analogs thereof to treat herpesvirus infection
US6303589B1 (en) * 1998-12-08 2001-10-16 Micro Flo Company Pentacyclic triterpenes
US6369101B1 (en) * 1999-02-26 2002-04-09 Regents Of The University Of Minnesota Therapeutic method to treat herpes virus infection
US6689767B2 (en) * 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757359B2 (en) 2008-01-11 2017-09-12 Reata Pharmaceuticals, Inc. Synthetic triterpenoids and methods of use in the treatment of disease
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US8124799B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8124656B2 (en) 2008-04-18 2012-02-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8258329B2 (en) 2008-04-18 2012-09-04 Reata Pharmaceuticals, Inc. Dehydroandrosterone analogs including an anti-inflammatory pharmacore and methods of use
US8394967B2 (en) 2008-04-18 2013-03-12 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US8440854B2 (en) 2008-04-18 2013-05-14 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17
US8440820B2 (en) 2008-04-18 2013-05-14 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9796668B2 (en) 2008-04-18 2017-10-24 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
USRE45325E1 (en) 2008-04-18 2015-01-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US20100048887A1 (en) * 2008-04-18 2010-02-25 Eric Anderson Compounds including an anti-inflammatory pharmacore and methods of use
US9090574B2 (en) 2008-04-18 2015-07-28 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9670147B2 (en) 2008-04-18 2017-06-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US20100048892A1 (en) * 2008-04-18 2010-02-25 Eric Anderson Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US10093614B2 (en) 2008-04-18 2018-10-09 Reata Pharmaceuticals, Inc. Antioxidant Inflamation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US8513436B2 (en) 2010-12-17 2013-08-20 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9884809B2 (en) 2010-12-17 2018-02-06 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9174941B2 (en) 2010-12-17 2015-11-03 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9290536B2 (en) 2011-03-11 2016-03-22 Reata Pharmaceuticals, Inc. C4 monomethyl triterpenoid derivatives and methods of use thereof
US9701709B2 (en) 2012-04-27 2017-07-11 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US8993640B2 (en) 2012-04-27 2015-03-31 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9593074B2 (en) 2012-09-10 2017-03-14 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9889143B2 (en) 2012-09-10 2018-02-13 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
CN104877015A (en) * 2014-02-28 2015-09-02 中国人民解放军军事医学科学院毒物药物研究所 Triterpene-polypeptide conjugate, drug composition and uses thereof

Also Published As

Publication number Publication date
US6689767B2 (en) 2004-02-10
AU9495901A (en) 2002-04-08
US20020119935A1 (en) 2002-08-29
WO2002026762A1 (en) 2002-04-04

Similar Documents

Publication Publication Date Title
AU629563B2 (en) Substituted 4-azatricyclo (22.3.1.0 4,9) octacos-18-ene derivatives
DE19916108C1 (en) With sugar residues substituted 1,4-benzothiazepine-1,1-dioxide derivatives, processes for their preparation and their use
US5721226A (en) Method for inhibiting angiogenesis using squalamine and squalamine steroid derivatives
DE69912313T2 (en) Colchinol derivatives as vascular damaging agent
JP2854006B2 (en) Valerolactone compounds and their preparation
US6767904B2 (en) Steroid derived antibiotics
KR100256861B1 (en) Alkali metal 8,9-dehydroestrone sulfate esters, pharmaceutical composition containing them and process for their production
DE69628353T2 (en) Benzopyran-containing compounds and their prodrug
DE69333771T2 (en) Pyran-2-ones and 5,6-dihydropyran-2-ones useful for treating hyperplasia and other diseases
JP3520071B2 (en) Cyclic peptide antifungal agents and their preparation
US6017892A (en) Method for accelerating marrow cell proliferation
CA1162535A (en) Process for the preparation of novel oximes derived from erythromycine a
EP0155096B1 (en) 17 beta-substituted-4-aza-5-alpha-androstenones and their use as 5-alpha-reductase inhibitors
DE69634492T2 (en) Drug precursors for thrombin inhibitors
US5698527A (en) Steroidal glycosides as antihyperlipidemic agents
Fujioka et al. Anti-AIDS agents, 11. Betulinic acid and platanic acid as anti-HIV principles from Syzigium claviflorum, and the anti-HIV activity of structurally related triterpenoids
US4331803A (en) Novel erythromycin compounds
EP1058552B1 (en) Steroid derived antibiotics
EP1311531B1 (en) Steroid derived antibiotics
CA2044746C (en) Polypeptide compound and a process for preparation thereof
DE69631141T2 (en) Biologically active peptides and uses their preparations and
CA2795320C (en) Method of treating obesity using antioxidant inflammation modulators
DE69829175T2 (en) Cyclosporin derivatives, their preparation and pharmaceutical preparations
US4351844A (en) Hypocholesterolemic hydrogenation products and process of preparation
US4220641A (en) Organic compounds